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E7 is an accessory protein that is not encoded by all papillomaviruses. The E7 amino terminus contains
two regions of similarity to conserved regions 1 and 2 of the adenovirus E1A protein, which are also
conserved in the simian vacuolating virus 40 large tumor antigen. The E7 carboxyl terminus consists of a
zinc-binding motif, which is related to similar motifs in E6 proteins. E7 proteins play a central role in the
human papillomavirus life cycle, reprogramming the cellular environment to be conducive to viral
replication. E7 proteins encoded by the cancer-associated alpha human papillomaviruses have potent
transforming activities, which together with E6, are necessary but not sufﬁcient to render their host
squamous epithelial cell tumorigenic. This article strives to provide a comprehensive summary of the
published research studies on human papillomavirus E7 proteins.
& 2013 Elsevier Inc. All rights reserved.Introduction
Unlike most review articles that are written from a particular
perspective and evaluate the literature accordingly, this article lists
and summarizes many of the countless research papers that have
been published over the years focused on biochemical properties
and biological activities of human papillomavirus (HPV) E7 proteins.
The intent is to be comprehensive and to present information as
unbiased as possible, rather than providing a critical assessment and
synthesis of this literature. A number of excellent and comprehen-
sive reviews on E7 have been published (Ghittoni et al., 2010;
Klingelhutz and Roman, 2012; McLaughlin-Drubin et al., 2012;
McLaughlin-Drubin and Munger, 2009; Moody and Laimins, 2010;
Pim and Banks, 2010; Wise-Draper and Wells, 2008) and this article
is to complement these reviews by providing unﬁltered and undi-
gested information. The goal is to empower investigators to connect
to the primary literature so that they can apply their own ﬁlters and
criteria to assess the “credibility” of the information in question. To
maximize accessibility of the information, most of the information is
organized and presented as tables.
The quality and usefulness of future versions of this article
depends upon crowdsourcing: missing or misinterpreted informa-
tion should be brought to the authors' attention and will be
corrected in revised versions of these tables and/or updatedll rights reserved.
ail Stop C1-015, Seattle, WA
CP 861, Boston, MA 02215,.version of this article. The most effective and efﬁcient way to
communicate changes will be to prepare a Table or Figure in the
same format as used here and send it as an attachment to
E7PAVEreview@gmail.com.
The HPVs are divided into genera (e.g., alpha, beta, mu, and
gamma), species (groupings of types within a genus) and types
based on amino acid identity, with types being the most closely
related (de Villiers et al., 2004). The alpha papillomaviruses cause
mucosal and cutaneous disease while the beta, mu and gamma
papillomaviruses cause cutaneous disease. Additionally, the alpha
genus is divided into low-risk and high-risk types based on
outcome of infection, with the former causing benign papillomas
and the latter lesions that can progress to carcinomas (zur Hausen,
2002). This review is a compendium of the biochemical and
biological activities of E7 proteins encoded by high-risk alpha
papillomavirus types (HPV16 and 31 in genus 9; HPV18 in genus
7), the low-risk alpha papillomavirus types (HPV6 and 11 in genus
10); the beta types (HPV5, 8 and 20 in genus 1; HPV38 in genus 2;
HPV49 in genus 3); a mu type (HPV1); and gamma types (HPV4 in
genus 1 and HPV108 in genus 6).Human papillomavirus E7 proteins
Amino acid sequences
HPV E7 proteins consist of approximately 100 amino acid
residues. There are no cellular proteins that share extensive
sequence similarities to E7, even though some E7 sequence motifs,
most notably the LXCXE sequence, are also found in cellular
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two regions of sequence similarity to the adenovirus (Ad) E1A
proteins. Relative to Ad E1A, these E7 sequences correspond to a
small portion of conserved region (CR) 1 and nearly the entire CR2
(Phelps et al., 1988). This sequence similarity extends to the simian
vacuolating virus 40 large tumor antigen (SV40 T) (Fig. 1) (Figge
and Smith, 1988) and provided a mechanistic explanation for the
functional similarities between Ad E1A and HPV16 E7 that were
discovered early on (Matlashewski et al., 1987; Phelps et al., 1988).
The CR1 and CR2 homology domains are conserved between
different HPV E7 proteins and are separated by a non-conserved
sequence of variable size and amino acid composition. The CR2
domain is followed by a second poorly conserved sequence
followed by the conserved carboxyl terminal zinc-binding site,
which consists of two CXXC domains separated by 29 to 30 amino
acid residues (Barbosa et al., 1989; McIntyre et al., 1993) (Fig. 1).
Papillomavirus E6 proteins contain two copies of a similar zinc-
binding motif. The HPV16 E7 C-terminal domain can be replaced
with the zinc-binding domain derived from E6 without apparent loss
of function (Mavromatis et al., 1997). It has been suggested that E6
and E7 might have evolved from a common ancestor (Cole and
Danos, 1987; Van Doorslaer et al., 2009). Consistent with such a
model, some papillomaviruses encode E7 but no E6 proteins (Ahola
et al., 1986; Chen et al., 2007; Nobre et al., 2009) whereas other
papillomaviruses encode E6 but no E7 proteins (Gottschling et al.,
2011; Stevens et al., 2008a, 2008b). In some cases E7 proteins contain
functional domains that in other papillomaviruses are encoded by
the E6 proteins. The Rhesus monkey papillomavirus 1 (MmPV1),Fig. 1. Sequence alignment of various HPV E7 proteins. (A) Schematic representation of t
shown as black boxes, variable sequences are shown in gray. (B) The HPV E7 amino t
adenovirus type 5 E1A protein (Ad5 E1A) and related sequences in the simian vacuolatin
motif in CR2 is shown. (C) The HPV E7 C-terminus contains two CXXC motifs that form a
any amino acid. Identical amino residues are highlighted by black boxes, amino acid res
details.which causes anogenital tract lesions similar to alpha HPVs, for
example, encodes an E7 protein with a C-terminal PDZ binding motif
(XS/TXV), which is a hallmark of high-risk alpha HPV E6 proteins
(Tomaic et al., 2009).
Some E7 proteins, including HPV16 E7 migrate slower on SDS
polyacrylamide gels than predicted from their molecular mass.
This is attributed to the high content of acidic amino acid residues,
particularly within the CR1 and CR2 homology domains
(Armstrong and Roman, 1992, 1993; Heck et al., 1992; Munger
et al., 1991). Neutralization of the negative charges by chemical
modiﬁcation of free carboxyl groups by 1-Ethyl-3-[3-dimethyl-
aminopropyl]carbodiimide (EDC) restored electrophoretic migra-
tion of HPV16 E7 to the predicted molecular mass (Armstrong and
Roman, 1993). In addition, the commonly used protease inhibitors,
tosyl-L-lysine chloromethyl ketone (TLCK) and tosyl-L-pheny-
lalanine chloromethyl ketone (TPCK), can chemically modify the
conserved cysteine residue in the E7 CR2 homology domain
(cysteine at residue 24, C24, in HPV16) causing slower migration
on SDS polyacrylamide gels (Stoppler et al., 1996).
Excellent antibodies exist for detection of untagged HPV16 E7:
the ED17 antibody recognizes an epitope near the LXCXE domain
and will not detect a deletion of residues 21–24 (del 21–24)
whereas the 8C9 antibody recognizes an epitope in the CR1
homology domain and will not detect the del 6–10 mutant
(Psyrri et al., 2004). In addition, epitope tagging has been widely
used. Amino-terminal tagging of HPV16 E7 can affect E7 stability
and binding to cellular proteins such as p600 (UBR4) and such
tagged forms can be transformation defective (Huh et al., 2005;he conserved sequence elements in a generic E7 protein. Conserved regions (CR) are
erminus contains two sequence elements that are similar to CR1 and CR2 of the
g virus 40 large tumor antigen (SV40 T). The position of the highly conserved LXCXE
zinc-binding site. The one letter code for amino acid (aa) residues is used; X denotes
idues with chemically similar side chains are marked with gray boxes. See text for
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C-terminus does not appear to affect biological activity (Huh
et al., 2005). On occasion, an estrogen receptor derived tag (ER)
that allows for conditional activation of E7 has been added to the
C-terminus (Genovese et al., 2008; Smith-McCune et al., 1999).
Subcellular localization
Felix Wettstein’s group was the ﬁrst to detect the HPV16 E7
protein in cervical carcinoma lines. They showed that HPV16 E7
localized to the soluble cytoplasmic fraction (Smotkin and
Wettstein, 1987). Nuclear localization of E7 has also been reported
(Greenﬁeld et al., 1991; Guccione et al., 2002; Sato et al., 1989;
Smith-McCune et al., 1999) and low-risk but not high-risk HPV E7
proteins can associate with PML bodies (Guccione et al., 2002).
HPV16 E7 was also detected in the nucleolus (Zatsepina et al.,
1997).
Consistent with nuclear and cytoplasmic E7 pools and activ-
ities, the HPV16 E7 protein contains nuclear localization as well as
nuclear export sequences and can shuttle between the two cellular
compartments (Knapp et al., 2009). It enters the nucleus through
nuclear pores using a RAN dependent pathway that does not
depend on classical karyopherins. Nuclear import is independent
of retinoblastoma tumor suppressor protein (pRB) binding but the
nuclear localization sequence has not been identiﬁed (Angeline
et al., 2003). The HPV16 E7 nuclear export sequence has been
mapped to amino acid residues 76–84, which are well conserved
in HPV E7 proteins (Fig. 1) (Knapp et al., 2009). RAN dependent,
karyopherin independent nuclear import has also been reported
for HPV11 E7 and the C-terminal zinc-binding domain was
necessary for nuclear transport (Piccioli et al., 2010).
Post-translational modiﬁcations
Phosphorylation
Early studies indicated that HPV16 is heavily phosphorylated
on serine residues (Smotkin and Wettstein, 1987). The HPV16 E7
protein contains a consensus phosphorylation site for casein
kinase II (CKII; EC 2.7.11.1) in the CR2 homology domain (Barbosa
et al., 1990; Firzlaff et al., 1989). This motif is conserved in SV40 T
and Ad E1A CR2 domains as well as in other alpha HPV E7 proteins
(Fig. 1) and some cellular LXCXE domain containing proteins
(Defeo-Jones et al., 1991). CKII phosphorylation was reported two
times faster for HPV18 E7 than HPV16 E7, which in turn was two
times faster than HPV6 E7 (Barbosa et al., 1990).
A complex of macrophage-inhibitory related factor protein
(MRP) 8 and 14 functions as a CKII inhibitor and causes decreased
CKII HPV16 E7 phosphorylation. MRP 8/14 levels were detectable
in normal but not in HPV immortalized human keratinocytes with
a concomitant four fold increase in CKII activity in HPV immorta-
lized cells (Tugizov et al., 2005).
S-phase-speciﬁc phosphorylation of Serine 71 in the HPV16 E7
C-terminal domain has also been described but the kinase is
unknown (Massimi and Banks, 2000). Although HPV16 E7 carrying
a mutation at this site has been tested for altered biological
activity, thus far only one assay has detected loss of function
(see Table 9).
The HPV6 E7 protein can be in vitro phosphorylated by protein
kinase C (PKC; EC 2.7.11.13) on threonine 7 in the CR1 homology
domain. Even though this residue is well conserved amongst many
HPV E7 proteins, the PKC recognition sequence [(R/K1–3/X2–0)-S/T-
(X2–0/R/K1–3)] is not conserved and the high-risk HPV16 E7 is not
PKC phosphorylated under similar experimental conditions
(Armstrong and Roman, 1995). However, phosphorylation of
HPV16 E7 at threonine residues 5 and 7 by dual-speciﬁcity
tyrosine phosphorylation-regulated kinase 1A (DYRK1A; EC2.7.12.1) has been described and linked to increased E7 stability
and transforming activity (Liang et al., 2008).
Ubiquitination
HPV16 E7 has a short half-life of less than 1 h (Smotkin and
Wettstein, 1987) and is degraded by the proteasome. A lysine-less
HPV16 E7 mutant was efﬁciently degraded through a ubiquitin
dependent mechanism, suggesting that HPV16 E7 can be amino
terminally ubiquitinated followed by proteasomal degradation
(Reinstein et al., 2000). Ubiquitination of the HPV16 E7 protein
by Ubch7 (UBE2L3) and a Cullin 1/Skp2-containing E3 ubiquitin
ligase has also been described (Oh et al., 2004a). Amino terminal
ubiquitination and proteasomal degradation has also been docu-
mented for HPV58 E7, which contains no lysine residues (Ben-
Saadon et al., 2004). Studies with estrogen-receptor (ER) fused
HPV E7 proteins showed that low-risk HPV6 and 11 E7 proteins are
also ubiquitinated but have a somewhat longer metabolic half-life
than similarly tagged high-risk HPV16 and 18 E7 proteins. Non-
conserved HPV11 E7 lysine residues 39 and 43 were identiﬁed as
targets for ubiquitin modiﬁcation but their mutation to arginine
residues caused decreased protein stability demonstrating that
ubiquitin modiﬁcation of these residues is not essential for rapid
proteasomal degradation (Genovese et al., 2011).
Other modiﬁcations
HPV E7 proteins have been reported to associate with trans-
glutaminase 2 (TGM2; EC 2.3.2.13). HPV18 E7, but not HPV16 E7, is
polyaminated at glutamine residues 87 or 88 in the C-terminal
domain. HPV18 E7 polyamination interferes with pRB binding and
functional inactivation (Jeon et al., 2003).
Evidence for additional post-translational modiﬁcation of HPV16
E7 is provided by the detection of three isoforms designated as E7a1
(17.5 kDa, IEP 4.68), E7a (17 kDa, IEP 6.18) and E7b (16 kDa, IEP 6.96).
These isoforms show differential localization to the nuclear and
cytoplasmic compartments (Valdovinos-Torres et al., 2008).
HPV E7 structures
Early glycerol gradient sedimentation studies with HPV16 E7
expressed in cervical cancer lines provided evidence that HPV16
E7 was present in macromolecular complexes (Smotkin and
Wettstein, 1987). HPV16 E7 forms a very stable extended structure
(Alonso et al., 2002) even though the amino terminal CR1/CR2
homology sequences represent an intrinsically disordered domain
(Garcia-Alai et al., 2007). E7 dimerization through the C-terminal
zinc-binding domain was observed when the protein was
expressed in Escherichia coli (McIntyre et al., 1993) or Saccharo-
myces cerevisiae (Clemens et al., 1995; Todorovic et al., 2011).
Detailed studies with puriﬁed recombinant HPV16 E7 showed that
E7 can form tetramers (Clements et al., 2000) and higher order
oligomers (Alonso et al., 2004), which may have chaperone
activity (Alonso et al., 2006), although the dimeric form was
predicted to be prevalent at physiological E7 concentrations
(Clements et al., 2000). Multimerization does not inhibit pRB
binding (Alonso et al., 2006; Clements et al., 2000). Metal
substitution studies with the E7 C-terminal zinc-binding domain
provided evidence for a compact, highly shielded zinc-thiolate
complex as evidenced by luminescence of the Cu(I)–E7 derivative
(Roth et al., 1992) similar to that observed with Cu(I)-metallothio-
neins (Beltramini et al., 1989).
Three-dimensional structures of the zinc-binding C-terminal
domains of HPV1 and HPV45 E7 have been reported (Liu et al.,
2006; Ohlenschlager et al., 2006). The structure of the C-terminal
HPV1 E7 domain encompasses amino acids 44–93 and was solved
by X-ray crystallography. It forms a dimer with a unique zinc-
Table 1
Biological activities of alpha HPV E7.
Biological process High-risk HPV E7





Maintains extrachromosomal HPV genomes +
(HPV31 only)
+ Flores et al. (2000), McLaughlin-Drubin et al. (2005),
Oh et al. (2004b), Thomas et al. (1999)
Ampliﬁes HPV genomes + ND Flores et al. (2000) and McLaughlin-Drubin et al. (2005)
Transformation
Transforms permanent rodent cells + − Banks et al. (1990), Barbosa et al. (1990), Edmonds and
Vousden (1989), Phelps et al. (1988), Vousden et al.
(1988), Watanabe et al. (1990), Watanabe et al. (1992)
Transforms primary rodent cells in cooperation with
RAS
+ − Banks et al. (1990), Chesters et al. (1990), Firzlaff et al.
(1991), Jewers et al. (1992), Massimi et al. (2008), Phelps
et al. (1988), Storey et al. (1990b)
Immortalizes primary human epithelial cells (often, but
not always, in cooperation with E6)
+ o Halbert et al. (1991, 1992), Jewers et al. (1992), Melillo
et al. (1994), Munger et al. (1989a), Sedman et al. (1991),
Wazer et al. (1995)
G1/S control
Induces DNA synthesis + + Banks et al. (1990), Morris et al. (1993), Watanabe et al.
(1992)
Induces PCNA in suprabasal cells + o Cheng et al. (1995)
Induces cell DNA synthesis in suprabasal cells + o Cheng et al. (1995), Chien et al. (2000), Collins et al.
(2005), Flores et al. (2000), Genovese et al. (2008)
Bypasses growth arrest + − Demers et al. (1996), Helt and Galloway (2001), Nguyen
et al. (2002), Ruesch and Laimins (1997), and Schulze
et al. (1998)
Abrogates p27KIP1 inhibition of CDK2 activity + ND Zerfass-Thome et al. (1996)
Mediates cyclin E/CDK2 phosphorylation of p107 + ND McIntyre et al. (1996)
Abrogates p21CIP1 inhibition of CDK2 activity + o Funk et al. (1997), Helt et al. (2002), Jones et al. (1997a)
Increases levels of p21CIP1 + − Martin et al. (1998)
Abrogates C/EBPα-mediated growth arrest, independent
of p21CIP1
+ + Muller et al. (1999)
Induces polα, and cyclin E in suprabasal cells + ND Chien et al. (2000)
Abrogates p16INK4A-mediated G1 arrest + ND Giarre et al. (2001)
Abrogates RAF-induced growth arrest by AKT-mediated
mislocalization of p21CIP1
+ ND Westbrook et al. (2002)
Activates CDK2 complexes + + He et al. (2003)
Increases expression of E2F2 + ND Longworth et al. (2005)
Mislocalizes p27KIP1 to the cytoplasm + ND Charette and McCance (2007)
Abrogates Miz-1-mediated transcription of p21CIP1 + − (Morandell et al. (2012)
Mitotic processes
Abrogates mitotic spindle checkpoint + − Thomas and Laimins (1998)
Causes multipolar mitoses/aberrant centrosome
duplication
+ − Duensing et al. (2000), Duensing and Munger (2003)
Induces tetrasomy + − Southern et al. (2004), Southern et al. (2001)
Induces anaphase bridges + ND Duensing and Munger (2002)
Decreases recruitment of γ-tubulin from cytoplasm to
centrosomes
+ ND Nguyen et al. (2007)
Disrupts NuMA/dynein network and induces
prometaphase delay
+ + Nguyen and Munger (2009)
Activates CHK2 + ND Moody and Laimins (2009)
Promotes mitotic entry + ND Spardy et al. (2009)
Abrogates postmitotic checkpoint + ND Heilman et al. (2009)
Upregulates PLK4 transcription + − Korzeniewski et al. (2011)
Prolongs G2 + ND Banerjee et al. (2011)
Upregulates cytoplasmic cyclin B, hyperphosphorylates
CDK1 and phosphorylates CDC25C in suprabasal cells
(induces prolonged G2 phase in suprabasal cells)
+ + (only cyclin B
analyzed
Banerjee et al. (2011)
Engages mitotic spindle checkpoint + ND Yu and Munger (2012)
Upregulates CDT1 + ND Fan et al. (2013)
Cell death/survival
Induces cell death in response to conﬂuence and/or
serum deprivation
+ ND Jones et al. (1997b)
Abrogates IGFBP-3-mediated apoptosis + ND Mannhardt et al. (2000)
Activates PKB/AKT + + Menges et al. (2006), Pim et al. (2005)
Abrogates Siva-1 mediated apoptosis + ND Severino et al. (2007)
Disrupts Siva-1: Bcl-XL complex formation + ND Severino et al. (2007)
Activates calpain + ND Darnell et al. (2007)
Activates caspase 3 and 7 in differentiated cells + + Moody et al. (2007)
Abrogates apoptosis through maintenance of activated
GSTP1
+ ND Mileo et al. (2009)
Induces autophagy in HFKs in response to metabolic
stress
+ ND Zhou and Munger (2009)
A. Roman, K. Munger / Virology 445 (2013) 138–168 141
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Biological process High-risk HPV E7





Induces double strand DNA breaks + Duensing and Munger (2002)
Activates the FA pathway + − Spardy et al. (2007)
Differentiation/senescence
Delays differentiation + + Collins et al. (2005), Flores et al. (2000), Jones et al.
(1997a), Zhang et al. (2006)
Abrogates pRB-induced ﬂat cell morphology + ND Brehm et al. (1999), Gonzalez et al. (2001), Helt and
Galloway (2001)
Enhances C/EBPα-mediated differentiation + ND Muller et al. (1999)
Abrogates senescence + + (PML-induced
senescence
Bischof et al. (2005), DeFilippis et al. (2003), Psyrri et al.
(2004), Wise-Draper et al. (2005)
Upregulates senescence inhibitor, DEK + − Wise-Draper et al. (2005)
Metabolism
Shifts the equilibrium of M2 pyruvate kinase (M2-PK) to
the less active, dimeric form
+ ND Zwerschke et al. (1999)
Activates allosteric acid α-glucosidase + ND Zwerschke et al. (2000)
Increases intracellular alkalinization potentially due to
increased activity of the Na+/H+ exchanger protein
+ ND Reshkin et al. (2000)
Cytokine modulation
Abrogates TGF-β-mediated repression of the c-myc
promoter
+ ND Pietenpol et al. (1990)
Abrogates TGF-β-mediated growth arrest + ND Lee et al. (2002b), Pietenpol et al. (1990)
Disrupts the formation of the ISGF3 (STAT1, STAT2, IRF-
9) complex
+ ND Barnard and McMillan (1999)
Inhibits cellular response to IFN-α + + Barnard et al. (2000)
Abrogates IRF-1-mediated transactivation + + Park et al. (2000), Perea et al. (2000)
Inhibits TNFα-mediated cell cycle arrest + ND Basile et al. (2001), Boccardo et al. (2010)
Inhibits TNFα-mediated epithelial differentiation + ND Basile et al. (2001)
Inhibits TNFα-induced apoptosis when protein synthesis
is inhibited
+ ND Basile et al. (2001), Thompson et al. (2001)
Inhibits TRAIL-induced apoptosis when protein
synthesis is inhibited
+ ND Basile et al. (2001)
Suppresses STAT-1 + − Hong et al. (2011), Thomas et al. (2001)
Abrogates TGF-β-mediated activation of a SMAD-
responsive promoter
+ + Habig et al. (2006), Lee et al. (2002b)
Inhibits TNFα-induced NFκB activity + ND Spitkovsky et al. (2002) Vandermark et al. (2012)
Increases expression of VEGF and IL-8 + ND Walker et al. (2011)
Protein stability
Increases steady state level of p53 Demers et al. (1994b), Jones et al. (1997b),
Seavey et al. (1999)
Destabilizes pRB + − Berezutskaya et al. (1997), Boyer et al. (1996)
Demers et al. (1994a), Jones and Munger (1997)
Destabilizes p107 + − Gonzalez et al. (2001), Helt and Galloway (2001)
Jones and Munger (1997)
Stimulates S4A proteasome subunit ATPase activity + ND Berezutskaya and Bagchi (1997)
Destabilizes p130 + + Genovese et al. (2008), Gonzalez et al. (2001),
Helt and Galloway (2001), Zhang et al. (2006)
Targets IGFBP-3 for proteasomal degradation + ND Santer et al. (2007)




− Huh et al. (2007), White et al. (2012)
Destabilizes claspin + ND Spardy et al. (2009)
Targets NHERF-1 for E6-mediated degradation + ND Accardi et al. (2011)
Stabilizes HIF-1α + ND Bodily et al. (2011b)
Stabilizes cyclin B during mitosis + ND Yu and Munger (2012)
Transcription
Transactives AdE2 promoter through E2F + + Edmonds and Vousden (1989), Firzlaff et al. (1991),
Phelps et al. (1992), Storey et al. (1990b), and Watanabe
et al. (1990)
Disrupts pRB but not p107 E2F complexes + ND Arroyo et al. (1993), Chellappan et al. (1992), Huang
et al. (1993), Wu et al. (1993), Zerfass et al. (1995)
Upregulates p107/E2F-responsive B-myb promoter + + Armstrong and Roman (1997), Lam et al. (1994)
Enhances c-jun-mediated transactivation + ND Antinore et al. (1996)
Activates the c-fos promoter + − Morozov et al. (1997)
Upregulates cyclin E promoter/mRNA + ND Martin et al. (1998), Vogt et al. (1999)
Induces p14ARF + ND Bates et al. (1998)
Stimulates M phase phosphoprotein 2 (MPP2)-mediated
transcription
+ - Luscher-Firzlaff et al. (1999)
Represses MHC I promoter + − Georgopoulos et al. (2000), Li et al. (2009)
Represses TAP-1 and LMP-2 promoters +HPV18 only +HPV6; −HPV11 Georgopoulos et al. (2000), and Heller et al. (2011)
Abrogates Skip-mediated transcriptional transactivation + ND Prathapam et al. (2001)
Activates E2F1-dependent, pRB-independent
transcription
+ o Hwang et al. (2002)
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Biological process High-risk HPV E7




Abrogates binding of SMAD to DNA + ND Lee et al. (2002b)
Activates the p73 promoter + - Brooks et al. (2002)
Upregulates the CDC25A promoter + ND Nguyen et al. (2002)
Abrogates BRCA 1 inhibition of ER-α transcriptional
activity
+ ND Zhang et al. (2005)
Abrogates BRCA1 inhibition of E Box transcriptional
activity
+ ND Zhang et al. (2005)
Abrogates BRCA1 repression of hTERT + ND Zhang et al. (2005)
Enhances c-myc dependent transcriptional
transactivation
+ − Wang et al. (2007)
Represses TLR9 promoter + ND Hasan et al. (2007)
Abrogates E2F6 mediated transcriptional repression + + McLaughlin-Drubin et al. (2008)
Induces the hTERT promoter + ND Liu et al. (2008)
Upregulates Nucleophosmin + ND McCloskey et al. (2010)
Activates HIF-1-mediated transcription + ND Bodily et al. (2011b)
Co-activation, epigenetic control
Abrogates BRG-1-mediated transcriptional repression of
c-fos
+ ND Lee et al. (2002a)
Abrogates p300 transcriptional co-activation function + o Bernat et al. (2003)
Down-regulates steroid receptor coactivator 1 (SRC-1)-
mediated transcription
Relocalizes SRC-1 to the cytoplasm
+ + Baldwin et al. (2006)
Abrogates FHL2 co-activation of beta-catenin and Fos/
Jun -dependent promoters
+ ND Campo-Fernandez et al. (2007)
Stimulates DNMT1 activity + ND Burgers et al. (2007)
Decreases the number of E2F6-PcG complexes + ND McLaughlin-Drubin et al. (2008)
Induces EZH2 + + Holland et al. (2008)
Upregulates SIRT1 + ND Allison et al. (2009)
Represses E-cadherin promoter through a DNMT-1-
dependent mechanism
+ ND Laurson et al. (2010)
Upregulates KDM6A/B + ND McLaughlin-Drubin et al. (2011)
Induces p16INK4A expression through H3K27
demethylation
+ ND McLaughlin-Drubin et al. (2011)
Modulation of cellular miR expression
Downregulates miR-203 + ND Melar-New and Laimins (2010)
Induces miR-16-1 + ND Zheng and Wang (2011)
Other activities
Increases levels of cyclin E throughout the cell cycle + ND Martin et al. (1998)
Elevates levels of CDK activity + − Martin et al. (1998)
Decreases polymerization of actin + ND Rey et al. (2000)
Abrogates TAP-1-mediated ATP-dependent peptide
transport into the ER
ND + Vambutas et al. (2001)
Induces membrane type 1 metalloproteinase and
activation of MMP2
+ ND Smola-Hess et al. (2005)
Inhibits NM23 expression/activities + ND Mileo et al. (2006)
Enhances AKT-dependent HFK migration + ND Charette and McCance (2007)
Upregulates MMP-9 activity + ND Cardeal et al. (2012)
FA, Fanconi anemia; H3K27, lysine 27 on histone H3; HFK, primary human foreskin keratinocytes; miR, micro-RNA; ND, not done; and PcG, polycomb group complex.
A. Roman, K. Munger / Virology 445 (2013) 138–168 143binding fold that is not closely related to the E6 zinc-binding
domain structure (Nomine et al., 2006). Many of the highly
conserved amino acid residues in the C-terminal domain are
surface exposed (Liu et al., 2006). The structure of the entire
HPV45 E7 protein was solved by nuclear magnetic resonance
spectroscopy (NMR). The amino terminal domain is unfolded
and C-terminal zinc-binding domain is involved in dimer forma-
tion (Ohlenschlager et al., 2006). There is good general agreement
between the two structures.Biological activities of alpha HPV E7 proteins
Interest in the HPV E7 protein was driven by early observations
that E6 and E7 were the only two high-risk alpha HPV genes that
are consistently expressed in human cervical carcinoma derived
cell lines. The high-risk alpha HPV E7 protein scored as the major
transforming protein in “standard” rodent cell basedtransformation assays (morphological transformation of NIH3T3
mouse ﬁbroblasts and, similar to Ad E1A, cooperation with RAS to
transform primary baby rat kidney cells). The recognition that E7
shares two blocks of sequence similarity with CR1 and CR2 of
Ad E1A provided the biochemical framework for many of the
following studies into “adenovirus E1A-like activities” of HPV E7
proteins.
The various biological activities that have been reported for high-
risk and low-risk alpha HPV E7 proteins are listed in Table 1. While we
have endeavored to indicate when a particular biochemical or
biological activity is true for only one HPV type, the reader should
be aware that a “+” in a column does not necessarily indicate similar
modes of action for different viruses. For example, while both HPV16
and 18 E7 destabilize pRB, the mechanisms must be different (White
et al., 2012); and although both HPV16 E7 and HPV6 E7 destabilize
p130, there appear to be distinct mechanisms (Barrow-Laing et al.,
2010). The reader is reminded to consult the primary literature to
evaluate the experimental data in this Table.
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alpha HPV E7 proteins represent functions related to the viral life cycle
and/or arise as a consequence of a speciﬁc replication strategy that
these viruses have adopted to establish a long-term persistent infec-
tion and/or produce viral progeny. Although the papillomaviruses are
thought to initially infect undifferentiated epithelial cells where the
viral genome is maintained at a low copy number, the productive
phase of the life cycle takes place in the differentiated compartment,
where cells would have normally exited the cell cycle. Since papillo-
maviruses are small and do not encode enzymes required for replica-
tion, the viruses must hijack cellular pathways if the virus is to
propagate. Viral life cycle phenotypes observed when E7 expression
is disrupted in the context of the intact genome are listed in Table 2.
The main function of the HPV E7 proteins is generally thought to be to
retain differentiating cells in a DNA synthesis competent state.
However, for at least some of the viruses, E7 is also required for
maintenance of the viral genome in undifferentiated cells. As seen in
Table 1, E7 affects many cellular processes, running the gamut from
cell cycle entry to cell death that would be pertinent to completion of
the virus cycle. As will be seen in subsequent tables, E7 accomplishes
this through direct or indirect interactions with an ever-expanding
number of proteins. The relevance of those interactions to the virus life
cycle remains, in many cases, to be established.
Experimental analyses of the viral life cycle generally involve
studies with monolayer human primary keratinocytes induced to
differentiate by the addition of calcium or suspension in methylcellu-
lose. Alternatively, in vitro engineered skin-like organotypic structures
are produced by growing conﬂuent keratinocytes at the air-liquid
interface on an artiﬁcial dermis or a reconstituted dermis to form a
structure that recapitulates key aspects of epithelial differentiation and
allows for viral genome ampliﬁcation, late gene expression and
production of viral progeny in differentiated layers of the epithelium.
An important caveat, however, is that these in vitro models for skin
differentiation have a very limited life span, i.e. even in the organotypic
cultures, the skin-like structure is formed but then rapidly disinte-
grates. Hence these experimental systems do not truly mimic the
“steady state” maintenance of squamous epithelia with continuous
asymmetric division of basal epithelial cells (a) to maintain the basal
layer and (b) to produce a continuous supply of differentiating cells to
replace the terminally differentiated, denucleated squames that are
continuously shed. Hence potential biological activities of E7 that may
be related to long-term persistent infection cannot be studied.Association of HPV E7 with cellular and viral proteins
The biochemical basis of the transforming activities of HPV E7
proteins initially was enigmatic since E7 lacked sequence motifs
characteristic of enzymes or DNA binding transcription factors.
However the observed functional and amino acid sequence simi-Table 2
Loss of E7 expression through insertion of a translation termination linker: effects on t
HPV Phenotype
HPV16 Retains ability to maintain extrachromosomal HPV genomes in undiffe
Fails to amplify viral DNA, induce unscheduled DNA synthesis, increase
expression of p53, p21CIP1, and mdm2, disrupt differentiation and indu
Reduces expression of L1
HPV18 Retains ability to maintain extrachromosomal HPV genomes
Fails to amplify HPV DNA and produce infectious virus
HPV31 Retains ability to transiently replicate extrachromosomal HPV genome
Fails to stably maintain extrachromosomal HPV genomes
HPV11 Fails to stably maintain extrachromosomal HPV genomes
NIKS; spontaneously immortalized human foreskin keratinocytes (Allen-Hoffmann et alarity to Ad E1A, also known to lack intrinsic enzymatic or speciﬁc
DNA binding activities, suggested similarities in the mechanisms
of action of these two classes of viral proteins (Phelps et al., 1988).
The Harlow and Branton groups published intriguing studies
revealing that Ad E1A associated with speciﬁc cellular proteins
and some of these proteins associated through CR1 and CR2
sequences that were known to be essential for cellular transfor-
mation (Egan et al., 1988; Harlow et al., 1986). The identiﬁcation of
the 110kd protein interacting with Ad E1A through CR2 sequences
as the retinoblastoma tumor suppressor gene product pRB, sup-
ported the concept that Ad E1A transforms cells through association
with cellular proteins (Whyte et al., 1988). SV40 T (DeCaprio et al.,
1988) and later the HPV16 E7 oncoprotein (Dyson et al., 1989) were
also shown to associate with pRB through the conserved LXCXE
sequence motif within CR2 (Fig. 1).
The similarities between HPV16 E7 and Ad E1A/SV40 T were
further elucidated with the construction of chimeric proteins. The
HPV16 E7 CR1 homology domain could functionally be replaced
with the related Ad E1A or SV40 T domains (Brokaw et al., 1994).
Interestingly, Ad E1A was able to functionally complement HPV16
E7 mutants in CR1 and CR2 and conversely HPV16 E7 was able to
functionally complement a pRB binding defective CR2 Ad E1A
mutant but was unable to complement a p300 binding defective
Ad E1A mutant in CR1 (Davies and Vousden, 1992).
An early example of the functional signiﬁcance of interaction of
HPV16 E7 with pRBwas the demonstration that an HPV16 E7mutated
in the CR2 pRB binding sequence could be complemented by E2F1
when cooperating with HPV16 E6 to immortalize HFKs; a mutation in
either CR1 or the CR2 CKII site, could not be complemented (Melillo
et al., 1994). The concept that Ad E1A, SV40 T and HPV16 E7
each exerts its biological activities through association with and
functional reprogramming of host cellular regulatory proteins or
protein complexes is now ﬁrmly established and a large number of
cellular proteins have been reported to associate with HPV E7.
Table 3 lists these proteins together with the method that was
originally used to discover a given interaction. There was no
attempt to distinguish between direct and indirect interactions.
Some proteins including E2F transcription factors and cyclin/
cyclin-dependent kinase (cdk) complexes have been reported to
interact both directly and indirectly with E7 and the criteria that
different research groups use to classify a given interaction as
“direct” or “indirect” are quite different. This table attempts to be
comprehensive and unbiased. Readers will need to consult the
primary literature to critically evaluate by their own criteria
whether a given interaction may be biologically relevant or not.
In addition to the proteins listed in Table 3, a large number of
other HPV E7-associated cellular proteins have been discovered
by several groups who performed large-scale yeast two hybrid
screens and/or characterized HPV E7-associated cellular protein
complexes by immunoafﬁnity puriﬁcation followed by masshe viral life cycle.
References
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Table 3
Cellular Proteins Reported to be Associated with HPV E7.
Gene name Original name Entrez Gene # Method High risk Low risk References
Actin ﬁlamentous
(F-actin)
GST + ND Rey et al. (2000)
ATM ATM 472 Co-IP HPV31 ND Moody and Laimins (2009)
BRCA1 BRCA1 672 GST/Co-IP + ND Zhang et al. (2005)
CAPN1 Mu-Calpain 823 Co-IP + ND Darnell et al. (2007)
CCNA1 Cyclin A 8900 Peptide bdg, GST + ND Dyson et al. (1992), McIntyre et al. (1996)
CCNE1 Cyclin E 898 GST + ND McIntyre et al. (1996)
CDK2 CDK2 1017 E7 peptide bdg; GST + + He et al. (2003), McIntyre et al. (1996),
Nguyen and Munger (2008)
CDKN1A p21CIP1 1026 GST/Co-IP + o/− Funk et al. (1997)
CDKN1B p27KIP1 1027 YTH + o (GST) Zerfass-Thome et al. (1996)
CENPC CENP-C1 1060 YTH + − Yaginuma et al. (2012)
CHD4 Mi2 1108 GST, YTH, + ND Brehm et al. (1999)
CHUK IKK-α 1147 Co-IP + ND Spitkovsky et al. (2002)
CUL1 Cullin 1 8454 GST + ND Oh et al. (2004a)
CUL2 Cullin 2 8453 AP-MS HPV16 only − Huh et al. (2007)
CUL3 Cullin 3 8452 AP-MS + + White et al. (2012)
CSNK2 Casein kinase II Kinase assay + o Barbosa et al. (1990), Firzlaff et al. (1989)
DNAJA3 hTid-1 9093 YTH + o Schilling et al. (1998)
DNMT1 DNMT1 1786 GST + ND Burgers et al. (2007)
DYRK1A DYRK1A 1859 Co-IP + ND Liang et al. (2008)
E2F1 E2F1 1869 GST/ivT + o Hwang et al. (2002)
E2F6 E2F6 1876 AP-MS + + McLaughlin-Drubin et al. (2008)
ENC1 Enc1 8507 AP-MS HPV18/45 only − White et al. (2012)
EP300 p300 2033 GST + o Bernat et al. (2003)
FHL2 FHL2 2274 GST + ND Campo-Fernandez et al. (2007)
FOXM1 MPP2 2305 YTH + ND Luscher-Firzlaff et al. (1999)
GAA Acid α-glucosidase 2548 YTH + ND Zwerschke et al. (2000)
GSTP1 GSTP1 2950 GST + ND Mileo et al. (2009)
HDAC1 HDAC1 3065 GST + ND Brehm et al. (1999)
HDAC2 HDAC2 3066 GST + ND Brehm et al. (1999)
HIF1A HIF1a 3091 Co-IP + + Bodily et al. (2011b)
HTRA1 HtrA1/Prss11 5654 Co-IP + ND Clawson et al. (2008)
IGFBP3 IGFBP-3 3486 YTH + o Mannhardt et al. (2000)
IKBKB IKK- 3551 Co-IP + ND Spitkovsky et al. (2002)
IRF1 IRF-1 3659 YTH + + Park et al. (2000)
IRF9 p48 10379 GST + ND Antonsson et al. (2006), Barnard and McMillan (1999)
JUN c-jun 3725 GST; YTH + ND Antinore et al. (1996)
KAT2B pCAF 8850 YTH + + Avvakumov et al. (2003), Huang and McCance (2002)
KCMF1 KCMF1 56888 AP-MS + + White et al. (2012)
MYC c-myc 4609 YTH + + Wang et al. (2007)
NCOA1 SRC1 8648 Co-IP + + Baldwin et al. (2006)
NME1 NM23-H1 4830 YTH + ND Mileo et al. (2006)
NME2 NM23-H2 4831 YTH + ND Mileo et al. (2006)
NUMA1 NuMA 4926 Co-IP, GST + o Nguyen and Munger (2009)
PKM M2-PK 5315 YTH + - Zwerschke et al. (1999)
PML PML 5371 GST + + Bischof et al. (2005)
PPP2R1/PPP2CA PP2A 5519/5515 GST/ivT + + Pim et al. (2005)
PSMC1 S4, 26S proteasome 5700 YTH + ND Berezutskaya and Bagchi (1997)
RAN Ran 5901 GST + ND Angeline et al. (2003), De Luca et al. (2003)
RB1 pRB 5925 Co-IP + o Berezutskaya et al. (1997), Boyer et al. (1996),
Dyson et al. (1989),
Firzlaff et al. (1991), Helt and Galloway (2001),
Jones and Munger (1997), Munger et al. (1989b)
RBL1 p107 5933 Peptide bdg + o Dyson et al. (1992), Gonzalez et al. (2001),
Helt and Galloway (2001), Zhang et al. (2006)
RBL2 p130 5934 Peptide bdg + o Dyson et al. (1992), Helt and Galloway (2001),
Zhang et al. (2006)
SIVA1 Siva-1 10572 YTH + ND Severino et al. (2007)
SMAD1 SMAD-1 4086 GST + + (HPV1, 8, 11) Habig et al. (2006)
SMAD2 SMAD-2 4087 GST + + (HPV1, 8, 11) Habig et al. (2006)
SMAD3 SMAD-3 4088 GST + + (HPV1, 8, 11) Habig et al. (2006)
SMAD4 SMAD-4 4089 GST + + (HPV1, 8, 11) Habig et al. (2006)
SMARCA4 BRG-1 6597 GST + - Lee et al. (2002a)
SNW1 Skip 22983 YTH + o Prathapam et al. (2001)
TAF1C TAF-110 9013 GST + ND Mazzarelli et al. (1995)
TAP1 TAP1 6890 Co-IP + + Vambutas et al. (2001)
TGM2 TGase2 7052 YTH/GST + + Jeon et al. (2003)
TBP TBP 6908 GST + + Mazzarelli et al. (1995)
TUBG1 γ-tubulin 7283 Co-localization + ND Nguyen et al. (2007)
UBR4 p600 23352 AP-MS + + Huh et al. (2005)
ZBTB17 Miz-1 7709 YTH + + Morandell et al. (2012)
ZER1 ZER1 10444 AP-MS HPV16 only − White et al. (2012)
AP-MS, afﬁnity puriﬁcation/mass spectrometry; bdg, binding; Co-IP, Co-immunoprecipitation; GST, Co-afﬁnity puriﬁcation through association with a glutathione-S-
transferase fusion protein; ivT, in vitro translation; YTH, yeast two-hybrid.
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identify “high-conﬁdence interactors”. These studies have been
critically reviewed (White and Howley, 2013) and the primary data
can be accessed in the form of supplementary tables with the
respective publications (Rozenblatt-Rosen et al., 2012; White et al.,
2012) and in Gulbahce et al., 2012 for the complete dataset of
HPV16 E7 associated proteins in HeLa cells performed by Huh and
colleagues (Huh et al., 2005). In the absence of further biological
validation, these data are best viewed as “hypothesis-generating”.
HPV E7 proteins have also been reported to associate with viral
proteins. In addition to forming homodimers and higher order
complexes (see the section entitled HPV E7 structures), HPV E7
proteins can associate with HPV E2 proteins (Gammoh et al., 2006;
Wang et al., 2012) and the Adeno-Associated Virus (AAV) Rep78
protein (Hermonat et al., 2000).Mutations and phenotypes of alpha HPV E7s
One of the advantages of working with viral proteins is that it is
straightforward to perform mutational genotype/phenotype ana-
lyses. Several groups performed extensive mutagenic analyses on
HPV16 E7 mostly targeting residues conserved between HPV E7,
Ad E1A and/or SV40 T, highly conserved residues in high-risk HPV
E7’s and/or residues that were different in low-risk and high-risk
HPV E7 proteins (Banks et al., 1990; Edmonds and Vousden, 1989;
Phelps et al., 1992; Watanabe et al., 1990). A more recent large-scale
mutagenic analysis of the C-terminal domain was inspired by the
available 3 dimensional structure of E7 and targeted both predicted
surface exposed and non-exposed residues (Todorovic et al., 2011).
An important caveat when interpreting phenotypes of E7
mutants concerns protein stability, conformation and localization.
Very few studies have exhaustively addressed protein stability of
the various mutants although many contemporary studies docu-
ment steady state levels in a given assay. Concerns about stability
and conformational alterations are somewhat ameliorated when a
given mutant retains some E7 activity. As noted in the section
entitled Amino acid sequences, studies with epitope tagged orTable 4
High-risk alpha HPV E7 CR1 mutants: biochemical properties.
HPV type Phenotype
HPV16
H2P Retains binding to pRB or p107
Retains binding to TBP
Retains binding to HDAC
Retains binding to IGFBP-3
Retains binding to Skip
Fails to block binding of pRB to E2F
Reduces binding to p300
Fails to bind p600
Fails to bind cullin 2 complex
Retains binding to DNMT1
Fails to bind to FHL2
del 3–5 (GDT) Retains binding to pRB
del 6–8 (PTL) Retains binding to pRB
del 6–10 (PTLHE) Retains binding to pRB or p107
Retains binding to S4 subunit of the pr
Retains binding to p21CIP1
Retains binding to HDAC
Retains binding to E2F/cyclin A comple
Very limited binding to IRF-1
Fails to bind p600
Retains binding to E2F6
Retains binding to NuMA
del 9–11 (HEY) Retains binding to pRB
del 12–14 (MLD) Retains binding to pRBother fusion proteins also have to be viewed with caution since
fusing heterologous sequences to the E7 amino terminus can alter
HPV16 E7 stability and function.
There is a further caveat when interpreting E7 mutant pheno-
types. As will become clear in the subsequent tables, more than
one protein binds to a particular amino acid sequence of E7.
Therefore, it is not trivial to implicate a given protein as respon-
sible for a speciﬁc function. Further experiments will be needed to
establish the identity of the effector protein.
Mutations and phenotypes of high-risk alpha HPV E7 proteins
Tables 4–9 summarize biochemical (Tables 4, 6 and 8) and
biological (Tables 5, 7 and 9) readouts, with high-risk alpha HPV
E7 mutants in the CR1 homology domain (Tables 4 and 5), CR2
homology domain (Tables 6 and 7) and C-terminal zinc-binding
domain (Tables 8 and 9), respectively. The location of the muta-
tions is depicted in Figs. 2–4. The most comprehensive collection
of mutations and their biochemical and biological studies exists
for HPV16 E7. Therefore, studies with other high-risk alpha HPVs
are listed when unique, informative mutants were tested or when
results differ substantially from studies performed with HPV16 E7.
Mutations and phenotypes of high-risk alpha HPV E7 proteins
The low-risk HPV E7 proteins show generally no or
decreased activity in most standard transformation assays.
Hence these proteins were “natural transformation defective
mutants”. Thus, in addition to standard mutagenic analyses,
which are summarized in Table 10 and Fig. 5, some investiga-
tors have constructed chimeric high-risk/low-risk E7 proteins.
Studies with HPV6/HPV16 chimeric E7 proteins showed that the
C-termini could be swapped without causing dramatic altera-
tions in transforming activity and that the amino terminus,
particularly the CR1 homology domain, contained sequences
that accounted for the unusual electrophoretic migration of
HPV16 E7 (see the section entitled Amino acid sequences)
whereas the CR2 homology domain appears to determine pRBReferences
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A. Roman, K. Munger / Virology 445 (2013) 138–168 147binding efﬁciency and transformation (Heck et al., 1992;
Munger et al., 1991; Pater et al., 1992). Such studies revealed
that changing a conserved aspartate residue (D) in HPV16 E7
to a glycine (G) caused a dramatic decrease in pRB binding
and transformation whereas mutation of the conserved corre-
sponding G to a D converted HPV6 E7 into a transforming
protein (Heck et al., 1992; Sang and Barbosa, 1992).Table 5




H2P Reduces BRK immortalization, transformat
Retains ability to transactivate the B-myb
Fails to bypass growth arrest induced by d
suspension, or TGF-β
Fails to destabilize pRB, p107, p130
Fails to increase Cyclin E levels
Fails to degrade IGFBP-3 and reduces abili
Fails to bypass pRB-induced quiescence in
Fails to extend HFK lifespan
Fails to induce tetrasomy in monolayer an
Fails to inhibit TNF-α-induced growth arre
H2P in the context of the intact genome Inefﬁcient immortalization of HFKs
Viral genomes may be extrachromosomal
Retains ability to produce late transcripts
Loss of differentiation-dependent reductio
del 3–5 (GDT) Reduces ability to transform primary rode
Retains ability to transactivate AdE2 prom
D4R Increases electrophoretic mobility of E7 pr
T5T7/DD Greatly reduces phosphorylation by DYRK1
Enhances ability to promote cell proliferat
del 6–8 (PTL) Substantially reduces transformation of pr
Retains ability to transactivate AdE2 prom
del 6–10 (PTLHE) Substantially reduces transformation
Reduces transactivation of AdE2 promoter
Reduces ability to transactivate cAMP-depe
Fails to bypass growth arrest induced by d
Fails to induce apoptosis in conﬂuent or se
Fails to stabilize p53
Fails to destabilize pRB
Fails to increase Cyclin E levels
Retains ability to inhibit IFN-α activity
Very limited ability to abrogate IRF-1-med
Retains ability to block binding of pRB to E
Reduces ability to bypass pRB-induced ﬂat
Retains ability to induce abnormal centros
Fails to transactivate the E2F
Fails to induce DNA synthesis in HPV E2
Fails to rescue HPV E2-expressing HeLa ce
Fails to induce tetraploidy in monolayer an
Retains ability to abrogate E2F6-mediated
E2F6-polycomb complexes
Fails to inhibit TNF-α-induced growth arre
del 6–10 (PTLHE) in the context of the
intact genome
Fails to delay HFK differentiation
Retains ability to maintain extrachromosom
HFKs
Reduces ability to induce E2F-responsive M
Reduces ability to induce cellular DNA syn
del 9–11 (HEY) Reduces ability to transform primary rode
Retains ability to transactivate AdE2 prom
del 12–14 (MLD) Substantially reduces ability to transform p
with RAS.
Reduces ability to transactivate AdE2 prom
HPV31
H2P in the context of the intact genome Retains ability to transiently replicate extr
Loses ability to maintain extrachromosoma
HPV18
H2P Retains ability to mediate cyclin E/cdk2 ph
BRK, baby rat kidney cells; cAMP, cyclic AMP; HFK, primary human foreskin keratin
HTB-85)Chimeric HPV11/HPV16 E7 proteins were constructed to map
key determinants of HPV16 E7 required to reduce major histo-
compatibility complex class I (MHC I) expression. Such studies
showed that the C-terminus of HPV16 E7 was responsible for
negatively regulating MHC I transcription. A more detailed analy-
sis documented a critical role for amino acids 78, 80, and 88 in the
HPV16 E7 C-terminal domain (Heller et al., 2011).References
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Table 6
High-risk HPV E7 CR2 mutants: biochemical activities.
HPV tpye Phenotype References
HPV16
del 15–17 (LQP) Retains binding to pRB Brokaw et al. (1994)
del 18–20 (ETT) Reduces binding to pRB Brokaw et al. (1994)
D21G Substantially reduces binding to pRB Heck et al. (1992)
D21S Retains binding to pRB or p107 Demers et al. (1996)
Retains binding to TBP Phillips and Vousden (1997)
del 21–24 (DLYC) Fails to bind pRB and p107 Demers et al. (1996), Jones et al. (1997b),
Munger et al. (1989b), Phelps et al. (1992)
Fails to bind E2F/cyclin A complex Arroyo et al. (1993)
Retains binding to S4 subunit of the proteasome Berezutskaya and Bagchi (1997)
Retains binding to hTid-1 Schilling et al. (1998)
Fails to bind IRF-1 Park et al. (2000)
Retains binding to E2F1 Hwang et al. (2002)
Retains binding to BRG-1 Lee et al. (2002a)
Retains binding to p600 Huh et al. (2005)
Retains binding to cullin 2 complex Huh et al. (2007)
Fails to binding γ-tubulin Nguyen et al. (2007)
Retains binding to CDK2 complexes in pRB
family member knockout cells
Reduces binding to CDK2 complexes in
pRB family member proﬁcient cells
Nguyen and Munger (2008)
Retains binding to E2F6 McLaughlin-Drubin et al. (2008)
Retains binding to NuMA Nguyen and Munger (2009)
Fails to bind phosphorylated ATM Moody and Laimins (2009)
C24G Substantially reduces binding to pRB and p107 Demers et al. (1996)
Retains binding to c-jun Antinore et al. (1996)
Reduces binding to TBP Phillips and Vousden (1997)
Retains binding to HDAC via Mi2β Brehm et al. (1999)
Retains binding to IGFBP-3 Mannhardt et al. (2000)
Fails to bind acid α-glucosidase Zwerschke et al. (2000)
Retains binding to p107 Gonzalez et al. (2001)
Retains binding to Skip Prathapam et al. (2001)
Substantially reduces binding to p300 Bernat et al. (2003)
Retains binding to PML IV Bischof et al. (2005)
Retains binding to DNMT1 Burgers et al. (2007)
Fails to bind γ-tubulin Nguyen et al. (2007)
Fails to bind FHL2 Campo-Fernandez et al. (2007)
Retains binding to Miz-1 Morandell et al. (2012)
C24S Substantially reduces binding to pRB Munger et al. (1989b), Phelps et al. (1992)
Retains binding to E2F/cyclin A complex Arroyo et al. (1993)
E26G Fails to bind E2F/cyclin A complex Arroyo et al. (1993)
Fails to bind pRB but retains binding to p107 Demers et al. (1996)
Reduces binding to TBP Phillips and Vousden (1997)
Retains binding to γ-tubulin Nguyen et al. (2007)
Fails to bind HIF-1α Bodily et al. (2011b)
E26Q Substantially reduces binding to pRB Munger et al. (1989b), Phelps et al. (1992)
Retains binding to S4 subunit of the proteasome Berezutskaya and Bagchi (1997)
N29D30/PP Retains binding to pRB Giarre et al. (2001)
D30EEEEDE33-37/QQQQQQ Reduces binding to pRB Firzlaff et al. (1991)
S31R Reduces binding to pRB Barbosa et al. (1990)
S31S32/AA Fails to bind F-actin Rey et al. (2000)
S31S32/RP Minimally reduces binding to pRB Barbosa et al. (1990), Firzlaff et al. (1991),
Heck et al. (1992)S31S32/CC
S31S32/AA
S31S32/DD
S31S32/RP Reduces binding to TBP Phillips and Vousden (1997)
S31S32/AA
S31S32/DD Retains binding to HDAC Brehm et al. (1999)
S31S32/RP Reduces binding to TBP Phillips and Vousden (1997)
Fails to bind Skip Prathapam et al. (2001)
Reduces binding to p300 Bernat et al. (2003)
S31S32/GG Reduces binding to pRB Jones et al. (1997b)
del 31–32 (SS) Retains binding to pRB Phelps et al. (1992)
S32W Minimally reduces binding to pRB Barbosa et al. (1990)
E35D36/DH Minimally reduces binding to pRB Barbosa et al. (1990)
del 35–37 (EDE) Retains binding to pRB Munger et al. (1989b), Phelps et al. (1992)
Retains binding to E2F/cyclin A complex Arroyo et al. (1993)
Retains binding to p21CIP1 Jones et al. (1997a)
Retains binding to S4 subunit of the proteasome Berezutskaya and Bagchi (1997)
Retains binding to hTid-1 Schilling et al. (1998)
Retains binding to HDAC Brehm et al. (1999)
Retains binding to CDK2 complexes in pRB family
member proﬁcient or deﬁcient cells
Nguyen and Munger (2008)
D36H Retains binding to pRB Demers et al. (1996)
HPV31
del 22–26 (LHCYE) Fails to bind pRB
Retains binding to HDAC 1/2
Longworth and Laimins (2004)
HPV18
Point mutations in aa 25–32 (PxDLLCxE) Fails to bind CENP-C Yaginuma et al. (2012)
del 24–27 (DLLC); Fails to bind pRB or p107 Chien et al. (2000)
C27S Fails to bind pRB and retains binding to p107 Chien et al. (2000)
E35E36E37/QQQ Retains binding to pRB and p107 Chien et al. (2000)
F-actin, ﬁlamentous actin.
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Table 7
High-risk alpha HPV E7 CR2 mutants: biological activities.
HPV type Phenotype References
HPV16
del 15–17 (LQP) Substantially reduces transformation of primary rodent cell in cooperation with
RAS
Brokaw et al. (1994)
Reduces ability to transactivate AdE2 promoter
del 18–20 (ETT) Substantially reduces transformation of primary rodent cell in cooperation with
RAS
Brokaw et al. (1994)
Reduces ability to transactivate AdE2 promoter
D21G Substantially reduces transformation of primary rodent cell in cooperation with
RAS
Heck et al. (1992)
D21S Retains ability to transform permanent rodent cells Edmonds and Vousden (1989)
Retains ability to bypass growth arrest induced by differentiation, DNA damage,
or TGF-β
Demers et al. (1996)
Retains ability to inhibit TNF-α-induced growth arrest Boccardo et al. (2010)
del 21–24 (DLYC) Fails to abrogate TGF-β repression of c-myc promoter Pietenpol et al. (1990)
Substantially reduces ability to transactivate AdE2 promoter Brokaw et al. (1994), Phelps et al. (1991, 1992),
Substantially reduces transformation of primary rodent cell in cooperation with
RAS
Brokaw et al. (1994), Phelps et al. (1992)
Reduces ability to transactivate cAMP-dependent c-fos promoter Morosov et al. (1994)
Fails to bypass growth arrest induced by differentiation, DNA damage, or TGF-β Demers et al. (1996), Helt and Galloway (2001)
Fails to destabilize pRB, p107, p130 Helt and Galloway (2001), Jones et al. (1997b)
Fails to stabilize p53
Fails to induce cell death in response to conﬂuence or serum/growth factor
deprivation
Jones et al. (1997b)
Reduces ability to inhibit p21CIP1 Jones et al. (1997a)
Fails to increase cyclin E levels Martin et al. (1998)
Fails to induce abnormal centrosome duplication/centriole synthesis Duensing et al. (2000), Duensing and Munger
(2003), Korzeniewski et al. (2011)
Fails to inhibit IFN-α activity Barnard et al. (2000)
Fails to abrogate IRF-1-mediated transactivation Park et al. (2000)
Fails to block binding of pRB to E2F Helt and Galloway (2001)
Fails to extend HFK lifespan
Fails to bypass pRB-induced ﬂat SAOS2 phenotype Gonzalez et al. (2001)
Fails to abrogate TGF-β activation of SMAD-responsive promoter, bind SMADs and
inhibit binding of SMADs to DNA
Lee et al. (2002b)
Retains ability to activate E2F1-dependent, pRB-independent transcription Hwang et al. (2002)
Retains ability to abrogate BRG-1-mediated repression of the c-fos promoter and
BRG-1-induced ﬂat cell formation in SW13 cells
Lee et al. (2002a)
Retains ability to be imported into the nucleus via a RAN-dependent pathway Angeline et al. (2003)
Fails to rescue E2-expressing HeLa cells from apoptosis or senescence Psyrri et al. (2004)
Fails to transactivate the E2F-responsive cyclin A promoter
Fails to induce DNA synthesis in HPV E2-expressing HeLa cells
Fails to induce tetrasomy in monolayer or raft cultures Southern et al. (2004)
Retains ability to abrogate E2F6-mediated transcriptional repression and disrupt
E2F6-polycomb complexes
McLaughlin-Drubin et al. (2008)
Fails to transactivate the E2F-responsive polycomb group EZH2 histone
methyltransferase gene
Holland et al. (2008)
Fails to increase expression of hTERT promoter Liu et al. (2008)
Fails to increase FANCD2-containing alternative lengthening of telomeres (ALT)-
associated promyelocytic leukemia bodies (APBs)
Spardy et al. (2008)
Retains disorganized metaphase phenotype (prometaphase delay) Nguyen and Munger (2009)
Fails to promote mitotic entry Spardy et al. (2009)
Fails to destabilize claspin
Fails to inhibit TNF-α-induced growth arrest Boccardo et al. (2010)
Retains ability to upregulate KDM6A/B histone H3 lysine 27-speciﬁc
demethylases
McLaughlin-Drubin et al. (2011)
Fails to increase PLK4 transcription Korzeniewski et al. (2011)
Fails to bind HIF-1α Bodily et al. (2011b)
Retains ability to increase HIF-1α-mediated transcription
Fails to inhibit cyclin B degradation Yu and Munger (2012)
del 21–24 (DLYC) in the context of
the intact genome
Fails to induce E2F-responsive MCM7 promoter in suprabasal cells Collins et al. (2005)
Fails to induce cellular DNA synthesis in suprabasal cells
Retains ability to maintain extrachromosomal copies of HPV genome in
undifferentiated HFKs
Fails to delay HFK differentiation
Fails to immortalize HFKs Bodily et al. (2011a)
C24G Fails to transform permanent rodent cells Barbosa et al. (1990), Edmonds and Vousden
(1989), Watanabe et al. (1990)
Substantially reduces ability to transactivate AdE2 promoter Edmonds and Vousden (1989), Watanabe et al.
(1990)
Retains CKII phosphorylation Barbosa et al. (1990)
Fails to upregulate B-myb promoter Lam et al. (1994)
Not required for E7 nuclear localization Fujikawa et al. (1994)
Fails to bypass growth arrest induced by differentiation, serum starvation, DNA
damage, or TGF-β
Demers et al. (1996), Nguyen et al. (2002)
Retains ability to enhance c-jun-mediated transactivation Antinore et al. (1996)
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Table 7 (continued )
HPV type Phenotype References
Fails to bypass growth arrest induced by differentiation, serum starvation,
DNA damage, or TGF-β
Demers et al. (1996), Nguyen et al. (2002)
Retains ability to enhance c-jun-mediated transactivation Antinore et al. (1996)
Fails to destabilize pRB but retains ability to destabilize p107 Gonzalez et al. (2001), Jones and Munger (1997)
Fails to increase cyclin E levels Martin et al. (1998)
Retains ability to abrogate C/EBPα-mediated growth arrest and enhance C/EBPα-
mediated differentiation
Muller et al. (1999)
Fails to bypass pRB-induced ﬂat SAOS2 phenotype Brehm et al. (1999), Gonzalez et al. (2001)
Retains ability to degrade IGFBP-3 and to abrogate IGFBP-3-mediated apoptosis Mannhardt et al. (2000)
Fails to activate acid α-glucosidase Zwerschke et al. (2000)
Fails to induce intracellular alkalinization Reshkin et al. (2000)
Fails to transactivate the p73 promoter Brooks et al. (2002)
Fails to abrogate RAF-induced growth arrest and relocalize p21CIP1 Westbrook et al. (2002)
Fails to upregulate CDC25A promoter Nguyen et al. (2002)
Fails to activate AKT in undifferentiated and differentiated HFKs Menges et al. (2006), Westbrook et al. (2002)
Reduces ability to abrogate p300-mediated HPV E2 transactivation Bernat et al. (2003)
Retains ability to induce abnormal centrosome duplication Duensing and Munger (2003)
Fails to increase acetylation of histone H3 on E2F-regulated promoters Zhang et al. (2004)
Retains ability to induce tetrasomy in monolayer and raft cultures Southern et al. (2004)
Fails to abrogate PML IV-mediated senescence Bischof et al. (2005)
Fails to disrupt PML IV:CBP-mediated p53 acetylation and p53-mediated
transcription
Fails to bind HIF-1α Bodily et al. (2011b)
Retains ability to increase HIF-1α-mediated transcription
Retains inhibition of Miz-1-dependent p21CIP1 transcription Morandell et al. (2012)
C24G in the context
of the intact genome
Reduces ability to immortalize HFKs Jewers et al. (1992)
Very inefﬁciently immortalizes HFKs Bodily et al. (2011a)
Causes reduced levels of viral transcripts in undifferentiated HFKs
Fails to produce late viral transcripts in differentiated HFKs
Fails to decrease pRB levels in differentiated cells
Fails to produce virus particles
C24S Fails to transform primary rodent cell in cooperation with RAS Phelps et al. (1992)
Substantially reduces ability to transactivate AdE2 promoter
Reduces ability to transactivate cAMP-dependent c-fos promoter Morosov et al. (1994)
Fails to degrade pRB Berezutskaya et al. (1997)
E26G Retains ability to upregulate B-myb promoter Lam et al. (1994)
Not required for E7 nuclear localization Fujikawa et al. (1994)
Fails to bypass growth arrest induced by differentiation, DNA damage, or TGF-β Demers et al. (1996)
Fails to increase cyclin E levels Martin et al. (1998)
Fails to destabilize pRB Gonzalez et al. (2001)
Retains ability to destabilize p107
Fails to bypass pRB-induced ﬂat SAOS2 phenotype
Fails to transactivate the p73 promoter Brooks et al. (2002)
Retains ability to induce abnormal centrosome duplication Duensing and Munger (2003)
Fails to inhibit TNF-α-induced growth arrest Boccardo et al. (2010)
Retains ability to increase HIF-1α-mediated transcription Bodily et al. (2011b)
E26G in the context
of the intact genome
Retains ability to immortalize HFKs Jewers et al. (1992)
Fails to immortalize HFKs Bodily et al. (2011a)
ND29/30PP Fails to destabilize pRB Giarre et al. (2001)
Fails to abrogate p16INK4A-mediated G1 arrest Giarre et al. (2001)
S31G Retains ability to transform primary rodent cells in cooperation with RAS Storey et al. (1990a)
S31R Reduces ability to transform established rodent cells Edmonds and Vousden (1989)
S31S32/RP Fails to induce S phase proteins in differentiated HFKs Bodily et al. (2011a)
S31S32/AA
S31S32/DD
Fails to be phosphorylated by CKII Barbosa et al. (1990)
S31S32/AA Reduces transformation of established rodent cells Barbosa et al. (1990)
S31S32/DD Fails to be phosphorylated by CKII Firzlaff et al. (1991)
Retains ability to transactivate the AdE2 promoter Firzlaff et al. (1991)
Fails to abrogate Skip-mediated transcriptional transactivation Prathapam et al. (2001)
S31S32/AA Reduces transformation of primary rodent cells in cooperation with RAS Firzlaff et al. (1991), Heck et al. (1992)
Fails to abrogate C/EBPα-mediated growth arrest and to enhance C/EBPα-
mediated differentiation
Muller et al. (1999)
S31S32/GG Reduces ability to bypass growth arrest induced by differentiation, DNA damage,
or TGF-β
Demers et al. (1996)
Reduces ability to destabilize pRB Jones et al. (1997b)
Reduces ability to stabilize p53
Reduces ability to induce cell death in response to conﬂuence or serum
deprivation
Reduces ability to transactivate the E2F Psyrri et al. (2004)
Reduces ability to induce DNA synthesis in HPV E2
Reduces ability to rescue E2-expressing HeLa cells from apoptosis or senescence
Fails to induce tetrasomy in monolayers but retains ability in raft cultures Southern et al. (2004)
Retains ability to immortalize HFKs Bodily et al. (2011a)
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S31S32/AA or DD in the context
of the intact genome
Reduces ability to produce viral particles but particles are infectious
S31S32/RP in the context of the
intact genome
Loses cis element required for late viral gene expression Bodily et al. (2011a)
Retains ability to support extrachromosomal replication of HPV genomes in
monolayers
Reduces ability to produce viral particles but particles are infectious
del 31–32 Retains ability to transform primary rodent cells in cooperation with RAS Phelps et al. (1992)
S32A Somewhat reduces transformation Barbosa et al. (1990), Storey et al. (1990a)
E35D36/DH Retains ability to transform rodent cells Edmonds and Vousden (1989)
Retains ability to be phosphorylated by CKII Barbosa et al. (1990)
del 35–37 (EDE) Retains ability to transform primary rodent cells in cooperation with RAS Phelps et al. (1992)
Substantially reduces CKII phosphorylation
Reduces ability to transactivate cAMP-dependent c-fos promoter Morosov et al. (1994)
Retains ability to degrade pRB Berezutskaya et al. (1997)
D36H Retains ability to bypass growth arrest induced by differentiation or TGF-β Demers et al. (1996)
HPV31
D21G in the context of the intact
genome
Retains ability to transiently replicate extrachromosomal HPV genomes Thomas et al. (1999)
Fails to maintain extrachromosomal HPV genomes
del 22–26 (LHCYE) in the context
of the intact genome
Somewhat reduces ability to stably maintain extrachromosomal HPV genomes Longworth and Laimins (2004)
Signiﬁcantly reduces growth rate Longworth and Laimins (2004)
Fails to extend life span
Fails to amplify HPV genomes upon differentiation
Fails to post-transcriptionally increase E2F2 in differentiated cells Longworth et al. (2005)
C24G in the context of the intact
genome
Fails to transiently replicate extrachromosomal HPV genomes Thomas et al. (1999)
Fails to maintain extrachromosomal HPV genomes
S31S32/AA in the context of the
intact genome
Retains ability to transiently replicate extrachromosomal HPV genomes Thomas et al. (1999)
Retains ability to maintain extrachromosomal copies of HPV genomes
HPV18
del 24–27 (DLLC) Fails to mediate cyclin E/cdk2 phosphorylation of p107 McIntyre et al. (1996)
Fails to induce unscheduled DNA synthesis in suprabasal cells Chien et al. (2000)
Fails to induce polα mRNA
Fails to upregulate PCNA or cyclin E, or p21CIP1
Fails to upregulate cytoplasmic cyclin B in suprabasal cells Banerjee et al. (2011)
Fails to upregulate cytoplasmic inactive CDC25C in suprabasal cells
C27G Fails to mediate cyclin E/cdk2 phosphorylation of p107 McIntyre et al. (1996)
C27S Fails to induce unscheduled DNA synthesis in suprabasal cells Chien et al. (2000)
Fails to induce polα mRNA
Fails to upregulate PCNA or cyclin E, or p21CIP1
S32S34/QQ Fails to be phosphorylated by CKII Chien et al. (2000)
Fails to upregulate PCNA, cyclin E, p21CIP1
Reduces ability to target p130 for degradation Genovese et al. (2008)
Fails to induce suprabasal DNA synthesis
Fails to upregulate expression of cytoplasmic inactive CDC25C in suprabasal cells Banerjee et al. (2011)
E35E36E37/QQQ Retains ability to increase polα mRNA Chien et al. (2000)
Fails to induce PCNA, cyclin E, and p21CIP1
Fails to be phosphorylated by CKII
Fails to induce suprabasal DNA synthesis
Reduces ability to target p130 for degradation Genovese et al. (2008)
Fails to upregulate cytoplasmic cyclin B in suprabasal cells Banerjee et al. (2011)
cAMP, cyclic AMP; HeLa, HPV18 positive human cervical adenocarcinoma line (ATCC Number CCL-2); HFK, primary human foreskin keratinocytes; SAOS2, pRB/p53 defective
human osteosarcoma cell line (ATCC Number: HTB-85); SW13 human adrenal gland/cortex carcinoma line (ATCC Number CCL-105).
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Studies with peptides yielded important insights into many
aspects of HPV E7 biology and biochemistry. Early studies by Rawls
and colleagues made use of synthetic versions of full length HPV16
E7 as well as isolated domains and allowed clean mapping of the
ability to induce DNA synthesis, to transcriptionally activate the Ad
E2 promoter, and to bind zinc ions (Rawls et al., 1990) (Table 11). A
later study with smaller peptides encompassing the LXCXE
domains provided information regarding the minimal domain
necessary for pRB binding (Jones et al., 1990) (Table 11). Subse-
quently, the structure of the minimal peptide bound to a pRB
fragment was solved (Lee et al., 1998). Many studies also took
advantage of synthesizing E7 peptides as fusions in E. coli to
identify E7 associated cellular proteins (see Table 3) or to rapidlymap domains necessary for interactions of E7 with cellular
proteins (Table 11).Cutaneous HPV E7 proteins
Beta, mu and gamma HPVs are associated with infections of
keratinized, cutaneous epithelia. A recent study however, identiﬁed a
large number of beta and gamma HPVs in the oral mucosa,
potentially suggesting that these cutaneous viruses may also colonize
a mucosal niche (Bottalico et al., 2011).
Cutaneous HPVs have attracted less experimental atten-
tion than alpha HPVs because they are mostly associated
with benign warts. Some beta HPVs associated warts, however,
can undergo malignant progression to invasive squamous
Table 8
High-risk alpha HPV E7 C-terminal mutants; biochemical activities.
HPV type Phenotype References
HPV16
E46A Retains binding to p600 Huh et al. (2005)
Retains binding to cullin
2 complex
Huh et al. (2007)
A50S Retains binding to pRB Demers et al. (1996)
Y52A Retains ability to dimerize
Reduces binding to pRB
Todorovic et al. (2012),
Todorovic et al. (2011)
del 52–56 (YNIVT) Fails to bind Skip Prathapam et al. (2001)
Retains binding to p300 Bernat et al. (2003)
Reduces binding to Miz-1 Morandell et al. (2012)
del 52–57
(YNIVTF)
Reduces binding to hTid-1 Schilling et al. (1998)
N53D Retains ability to dimerize
Fails to bind cullin 2
Todorovic et al. (2012),
Todorovic et al. (2011)
Reduces binding to pRB
V55T Fails to dimerize Todorovic et al. (2012),
Todorovic et al. (2011)Fails to bind cullin 2
Increases binding to pRB
V55F57M84/AAA Reduces binding to GSTP1 Mileo et al. (2009)
F57A Fails to dimerize Todorovic et al. (2012),
Todorovic et al. (2011)Increases binding to pRB
C58C91/GG Retains binding to pRB and
p107
Demers et al. (1996)
Retains binding to p27KIP1 Zerfass-Thome et al. (1996)
Reduces binding to TBP Phillips and Vousden
(1997)
Retains binding to IRF-1 Park et al. (2000)
Fails to bind acid α-glucosidase Zwerschke et al. (2000)
Fails to bind BRG-1 Lee et al. (2002a)
Fails to bind TGase 2 Jeon et al. (2003)
Fails to dimerize Todorovic et al. (2011)
C59S Retains ability to dimerize
Reduces binding to pRB
Todorovic et al. (2012),
Todorovic et al. (2011)
K60E Retains ability to dimerize Todorovic et al. (2011)
D62K Retains ability to dimerize
Increases binding to pRB
Todorovic et al. (2012),
Todorovic et al. (2011)
S63D Retains ability to dimerize
Fails to bind cullin 2
Todorovic et al. (2012),
Todorovic et al. (2011)
Reduces binding to pRB
T64D Retains ability to dimerize
Reduces binding to pRB
Todorovic et al. (2012),
Todorovic et al. (2011)
L65A Fails to dimerize Todorovic et al. (2011)
L65R66L67/AAA Retains binding to p300 Bernat et al. (2003)
R66E Retains ability to dimerize
Fails to bind cullin 2
Todorovic et al. (2012),
Todorovic et al. (2011)
Increases binding to pRB
L67R Retains partial or full binding to
pRB
Avvakumov et al. (2003),
Brehm et al. (1999)
Fails to bind HDAC and Mi2β Brehm et al. (1999)
Fails to bind pCAF Avvakumov et al. (2003)
Reduces binding to PML IV Bischof et al. (2005)
Retains ability to dimerize Todorovic et al. (2011)
C68V69Q70/AAA Retains binding to p600 Huh et al. (2005)
Fails to bind cullin 2 complex Huh et al. (2007)
Retains binding to E2F6 McLaughlin-Drubin et al.
(2008)
V69A Fails to dimerize Todorovic et al. (2011)
S71I Retains binding to pRB and p107 Demers et al. (1996), Jones
et al. (1997b)
Retains binding to HDAC Brehm et al. (1999)
Retains binding to IRF-1 Park et al. (2000)
Retains binding to BRG-1 Lee et al. (2002a)
Retains binding to TGase 2 Jeon et al. (2003)
Retains binding to pCAF Avvakumov et al. (2003)
T72D Retains ability to dimerize
Fails to bind cullin 2
Todorovic et al. (2012),
Todorovic et al. (2011)
H73E Retains ability to dimerize
Fails to bind cullin 2
Todorovic et al. (2012)
Todorovic et al. (2011)
V74T Retains ability to dimerize
Increases binding to pRB
Todorovic et al. (2012,
Todorovic et al. (2011)
del 75–77 (DIR) Retains ability to degrade pRB Helt and Galloway (2001)
Retains binding to p300 Bernat et al. (2003)
I76A Fails to dimerize Todorovic et al. (2011)
R77E Fails to dimerize Todorovic et al. (2011)
Reduces binding to pRB
del 78–85
(TLEDLLMG)
Reduces binding to hTid-1 Schilling et al. (1998)
Table 8 (continued )
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L79A Fails to dimerize Todorovic et al. (2011)
del 79–83 (LEDLL) Fails to bind TBP Massimi et al. (1997)
Fails to bind M2-PK Zwerschke et al. (1999)
Signiﬁcantly reduces binding to
IGFBP-3
Mannhardt et al. (2000)
Fails to bind acid α-glucosidase Zwerschke et al. (2000)
Retains binding to p300 Bernat et al. (2003)
Retains binding to p600 Huh et al. (2005)
Fails to bind FHL2 Campo-Fernandez et al.
(2007)
Fails to bind cullin 2 complex Huh et al. (2007)
Retains binding to E2F6 McLaughlin-Drubin et al.
(2008)
Fails to bind NuMA Nguyen and Munger
(2009)
Reduces binding to Miz-1 Morandell et al. (2012)
E80D81/KK Retains ability to dimerize Todorovic et al. (2011)
L82L83/RR Fails to bind HDAC Brehm et al. (1999)
Reduces binding to PML IV Bischof et al. (2005)
Fails to bind DNMT1 Burgers et al. (2007)
L82L83M84G85/
AAAD
Retains ability to dimerize Todorovic et al. (2011)
M84S Retains ability to dimerize;
Increases binding to pRB
Todorovic et al. (2011)
G85A Retains ability to dimerize;
Reduces binding to pRB
Todorovic et al. (2012,
Todorovic et al. (2011)
T86D Fails to dimerize Todorovic et al. (2011)
L87A Fails to dimerize Todorovic et al. (2011)
I89V90/AA Fails to dimerize Todorovic et al. (2011)
C91G Reduces dimerization Todorovic et al. (2011)
Fails to bind c-jun Antinore et al. (1996)
Fails to bind HDAC Brehm et al. (1999)
Fails to bind BRCA1 Zhang et al. (2005)
Reduces binding to PML IV Bischof et al. (2005)




Signiﬁcantly reduces binding to
hTid-1
Schilling et al. (1998)
Retains binding to p600 Huh et al. (2005)
Fails to bind cullin 2 complex Huh et al. (2007)
Fails to bind E2F6 McLaughlin-Drubin et al.
(2008)
Fails to bind NuMA Nguyen and Munger
(2009)
Increases binding to HIF-1α Bodily et al. (2011b)
del 91–94 (CPIC) Signiﬁcantly reduces binding to
hTid-1
Schilling et al. (1998)
P92A Retains ability to dimerize
Increases binding to pRB
Todorovic et al. (2012,
2011)
I93T Retains ability to dimerize
Increases binding to pRB
Todorovic et al. (2012),
Todorovic et al. (2011)
Q96K97P98/EEA Retains ability to dimerize Todorovic et al. (2012,
2011)Reduces binding to Cullin 2
HPV31




Moody and Laimins (2009)
Increases binding to HIF-1α Bodily et al. (2011b)








del 79–83 (LQELL) Retains binding to HDAC 1/2 Longworth and Laimins
(2004)
L82L83/RR Retains binding to HDAC 1/2 Longworth and Laimins
(2004)





C65S Reduces binding to Zn2+ by 50% McIntyre et al. (1993)
C65C98/SS Fails to bind Zn2+ McIntyre et al. (1993)
del 65–68/98–101
(CCKC/ CPWC)
Fails to bind c-myc Wang et al. (2007)
C98S Reduces binding to Zn2+ by 50% McIntyre et al. (1993)
TGase 2, transglutaminase 2.
A. Roman, K. Munger / Virology 445 (2013) 138–168152
Table 9
High-risk alpha HPV E7 C-terminal mutants; biological activities.
HPV type Phenotype References
HPV16
E46A Retains ability to destabilize pRB, p107, p130 Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to bypass DNA damage checkpoints Retains ability to extend HFK lifespan
A50S Retains ability to bypass growth arrest induced by differentiation, DNA damage, or TGF-β Demers et al. (1996)
Retains ability to destabilize pRB Psyrri et al. (2004)
Retains ability to transactivate the E2F-responsive cyclin A promoter
Retains ability to induce DNA synthesis and block senescence in HPV E2-expressing HeLa cells
Reduces ability to rescue E2-expressing HeLa cells from apoptosis or senescence
Signiﬁcantly reduces ability to induce tetrasomy in monolayer and raft cultures Southern et al. (2004)
H51A Retains ability to destabilize pRB Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to bypass DNA damage checkpoints
Y52A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Reduces ability to overcome cell cycle arrest
del 52–56 (YNIVT) Signiﬁcantly reduces ability to abrogate Skip-mediated transcriptional transactivation Prathapam et al. (2001)
Reduces inhibition of Miz-1-dependent p21CIP1 transcription Morandell et al. (2012)
del 52–57 (YNIVTF) Fails to stimulate MPP2 (FOXM1)-dependent transcription Luscher-Firzlaff et al.
(1999)
N53D Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
del 54–61 (IVTFCCKC) Retains ability to transactivate the AdE2 promoter Watanabe et al. (1990)
Fails to transform permanent rodent cells
V55T Increases ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
V55F56M84/AAA Reduces protection of GSTP1 from inactivation through oxidation Mileo et al. (2009)
Reduces protection of cells from JNK-mediated apoptosis in response to UV
F57A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
C58C91/GG Reduces ability to transform permanent rodent cells Edmonds and Vousden
(1989)
Retains ability to transactivate the B-myb promoter Lam et al. (1994)
Fails to bypass growth arrest induced by differentiation, DNA damage, or TGF-β Demers et al. (1996)
Fails to abrogate p27KIP1-mediated inhibition of CDK2 Zerfass-Thome et al.
(1996)
Fails to abrogate IRF-1 mediated transactivation Park et al. (2000)
Fails to abrogate BRG-1-mediated repression of the c-fos promoter and BRG-1-induced ﬂat cell
formation in SW13 cells
Lee et al. (2002a)
Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
C59S Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
K60E Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
D62K Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
D62S63T64/AAA Retains ability to destabilize pRB Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to bypass DNA damage checkpoints
S63D Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
T64D Increases ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
L65A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
L65R66L67/AAA Retains ability to block binding of pRB to E2F Helt and Galloway
(2001)
del 65–72 (LRLCVQST) Fails to stimulate MPP2 (FOXM1)-dependent transcription Luscher-Firzlaff et al.
(1999)
R66A Retains ability to destabilize pRB Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to bypass DNA damage checkpoints
R66E Increases ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
L67R Fails to bypass pRB-induced quiescence in SAOS2 cells Brehm et al. (1999)
Fails to abrogate growth arrest induced by serum deprivation Nguyen et al. (2002)
Fails to upregulate CDC25A promoter
Fails to transactivate E2F-dependent promoters Avvakumov et al. (2003)
Fails to increase acetylation of histone H3 on E2F-regulated promoters Zhang et al. (2004)
Fails to abrogate PML IV-mediated senescence Bischof et al. (2005)
Fails to induce centriole overduplication Korzeniewski et al.
(2011)Fails to increase PLK4 transcription
Fails to increase HIF-1α-mediated transcription Bodily et al. (2011b)
Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
L67R in the context of the intact genome Retains ability to immortalize HFKs Bodily et al. (2011a)
Retains ability to maintain extrachromosomal copies of viral genomes
Retains ability to activate late viral transcription in differentiated cells
May be compromised in ability to decrease pRB level and induce cell cycle proteins
Fails to produce viral particles.
C68V69Q70/AAA Retains ability to destabilize pRB, p107, p130 Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
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Table 9 (continued )
HPV type Phenotype References
Retains ability to abrogate pRB-induced ﬂat SAOS2 cell morphology
Fails to bypass DNA damage checkpoints
Fails to extend HFK lifespan
Fails to inactivate p21CIP1 Helt et al. (2002)
Fails to bypass differentiation-induced growth arrest
Limited increase in FANCD2-containing alternative lengthening of telomeres (ALT)-associated
promyelocytic leukemia bodies (APBs)
Spardy et al. (2008)




Retains ability to inhibit TNF-α-induced growth arrest Boccardo et al. (2010)
C68V69Q70/AAA in the context of the
intact genome
Retains ability to immortalize HFKs Bodily et al. (2011a)
Retains ability to maintain extrachromosomal copies of viral genomes
Retains ability to activate late viral transcription in differentiated cells
May be compromised in ability to decrease pRB level and induce cell cycle proteins
Reduces ability to produce viral particles but particles are infectious.
V69A Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
S71I Retains ability to transform permanent rodent cells Edmonds and Vousden
(1989)
Retains ability to be phosphorylated by CKII Barbosa et al. (1990)
Retains ability to bypass growth arrest induced by differentiation, DNA damage, or TGF-β Demers et al. (1996)
Retains ability to destabilize pRB Jones et al. (1997b)
Retains ability to stabilize p53
Retains ability to abrogate cell death induced by conﬂuence or serum deprivation
Retains ability to abrogate IRF-1-mediated transactivation Park et al. (2000)
Retains ability to abrogate BRG-1-mediated repression of the c-fos promoter and BRG-1-induced ﬂat
cell formation in SW13 cells
Lee et al. (2002a)
Retains ability to abrogate pRB-induced ﬂat SAOS2 cell morphology Avvakumov et al.
(2003)
Retains increased acetylation of histone H3 on E2F-regulated promoters Zhang et al. (2004)
Signiﬁcantly reduces ability to induce tetrasomy in monolayer and raft cultures Southern et al. (2004)
T72D Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
T72H73V74/AAA Retains ability to degrade pRB Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to override DNA damage checkpoints
H73E Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
V74T Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
del 75–77 (DIR) Retains ability to block binding of pRB to E2F Helt and Galloway
(2001)Retains ability to degrade pRB
I76A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
R77A Retains ability to degrade pRB Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to override DNA damage checkpoints
R77E Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
L79A Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
del 79–83 (LEDLL) Fails to shift the equilibrium of M2 pyruvate kinase (M2-PK) to the less active, dimeric form Zwerschke et al. (1999)
Fails to degrade IGFBP-3 and to abrogate IGFBP-3-mediated apoptosis Mannhardt et al. (2000)
Fails to activate acid α-glucosidase Zwerschke et al. (2000)
Retains the ability to destabilize pRB, p107, p130 Helt and Galloway
(2001)Retains ability to block binding of pRB to E2F
Retains ability to abrogate pRB-induced quiescence of SAOS2 cells
Fails to bypass DNA damage checkpoints
Fails to extend HFK lifespan
Fails to inactivate p21CIP1 Helt et al. (2002)
Fails to bypass differentiation-induced growth arrest
Fails to inhibit TBP binding to DNA Maldonado et al. (2002)
Limits increase in FANCD2-containing alternative lengthening of telomeres (ALT)-associated
promyelocytic leukemia bodies (APBs)
Spardy et al. (2008)




Fails to induce disorganized metaphase phenotype (prometaphase delay) Nguyen and Munger
(2009)
Retains ability to inhibit TNF-α-induced growth arrest Boccardo et al. (2010)
Reduces inhibition of Miz-1-dependent p21CIP1 transcription Morandell et al. (2012)
Fails to inhibit cyclin B degradation Yu and Munger (2012)
del 79–86 (LEDLLMGT) Fails to stimulate MPP2 (FOXM1)-dependent transcription Luscher-Firzlaff et al.
(1999)
E80Q Fails to repress MHC I expression Heller et al. (2011)
E80D81/KK Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
E80E81/QQ Gains ability to be polyaminated by TGase 2 Jeon et al. (2003)
L82L83/RR Fails to abrogate PML IV-mediated senescence Bischof et al. (2005)
Fails to disrupt PML IV:CBP-mediated p53 acetylation and p53-mediated transcription
L82L83M84G85/AAAD Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
M84S Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
G85A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Fails to overcome cell cycle arrest
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T86D Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
L87A Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
I89V90/AA Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
C91G Limits ability to transform permanent rodent cells Edmonds and Vousden
(1989)
Fails to immortalize HFKs Jewers et al. (1992)
Fails to enhance c-JUN-mediated transactivation Antinore et al. (1996)
Fails to abrogate BRCA1 inhibition of ER-α-mediated transcription Zhang et al. (2005)
Fails to abrogate PML IV-mediated senescence Bischof et al. (2005)
Reduces ability to cooperate with RAS to transform primary rodent cells Todorovic et al. (2011)
C91G in context of intact genome Fails to immortalize HFKs (Jewers et al. (1992),
Reduces efﬁciency of immortalization of HFKs (Bodily et al. (2011a)
Retains ability to maintain extrachromosomal HPV genomes
Retains ability to produce late viral transcripts
Reduces proliferation and retention of nuclei in organotypic rafts
C91S Fails to stimulate S4A proteasome subunit ATPase activity Berezutskaya and
Bagchi (1997)
Retains ability to degrade pRB Gonzalez et al. (2001)
Retains ability to induce abnormal centrosome duplication Duensing and Munger
(2003)
Fails to abrogate E2F6-mediated transcriptional repression and decrease E2F6-PcG complexes McLaughlin-Drubin
et al. (2008)
Fails to increase HIF-1α-mediated transcription Bodily et al. (2011b)
C91S in context of intact genome Retains ability to immortalize HFKs Bodily et al. (2011a)
Retains ability to maintain extrachromosomal HPV genomes
Retains ability to decrease the level of pRB
Retains ability to produce late viral transcripts in differentiated HFKs
Reduces proliferation and retention of nuclei in organotypic rafts
del C91-94 (CPIC) Substantially reduces ability to transactivate the AdE2 promoter Storey et al. (1990a),
Watanabe et al. (1990)
P92A Increases ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
I93T Retains ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Q96K97P98/EEA Reduces ability to transform primary rodent cells in cooperation with RAS Todorovic et al. (2011)
Reduces pRB degradation
HPV31
L67R in the context of the intact genome Fails to stably maintain extrachromosomal HPV genomes Longworth and Laimins
(2004)Fails to extend life span
Fails to increase E2F2 transcription and to inhibit binding of HDAC 1/3 to E2F2 promoter in
differentiated cells
Longworth et al. (2005)
C68V69Q70/AAA in the context of the
intact genome
Retains ability to stably maintain extrachromosomal HPV genomes Longworth and Laimins
(2004)Retains ability to extend life span.
Limits ability to amplify viral DNA upon differentiation
S71C in context of intact genome Retains ability to stably maintain extrachromosomal HPV genomes Longworth and Laimins
(2004)Retains ability to extend life span
Retains ability to amplify HPV genomes upon differentiation
del 79–83 (LQELL) in the context of the
intact genome
Some reduction in the ability to stably maintain extrachromosomal copies of viral genomes Longworth and Laimins
(2004)Retains ability to extend life span
Fails to amplify HPV genome upon differentiation
L82L83/RR in the context of the intact
genome
Retains ability to extend life span Longworth and Laimins
(2004)Somewhat reduces ability to stably maintain extrachromosomal HPV genomes
Fails to amplify HPV genomes upon differentiation.
C91G in context of intact genome Signiﬁcant reduces ability to stably maintain extrachromosomal copies of viral genomes Longworth and Laimins
(2004)Fails to immortalize cells
HPV18
C65S Fails to cooperate with RAS to transform primary rodent cells McIntyre et al. (1993)
C65C98/SS Fails to cooperate with RAS to transform primary rodent cells McIntyre et al. (1993)
del 65–68/98–101 (CCKC/ CPIC) Fails to enhance c-myc dependent transcriptional transactivation Wang et al. (2007)
Q87Q88/RR Fails to be polyaminated by TGase 2 Jeon et al. (2003)
C98S Fails to cooperate with RAS to transform primary rodent cells McIntyre et al. (1993)
BRK, baby rat kidney cells; HFK, primary human foreskin keratinocytes; UV, ultraviolet; SAOS2, pRB/p53 defective human osteosarcoma cell line (ATCC Number: HTB-85);
SW13 human adrenal gland/cortex carcinoma line (ATCC Number CCL-105); TGase2, transglutaminase 2.
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suppressed patients or in individuals affected by Epidermodys-
plasia verruciformis (EV), a rare autosomal recessive genetic
disease. EV-associated cancers were the ﬁrst malignant tumors
that were linked to HPV infections (reviewed in Pﬁster (2003)).
Very few cell-based assays have been described to analyze the
potential transforming activities of beta HPV E7 proteins.
Table 12 lists biological and biochemical activities and a limitedamount of mutational genotype/phenotype data for this group
of viruses.
Chimeras between the alpha HPV16 E7 and the mu HPV1 E7
have also been informative. While both E7 proteins bind pRB with
high efﬁciency, only HPV16 E7 degrades it. Studies with chimeras
revealed that the HPV16 E7 CR2 domain, in the background of
HPV1 E7 could degrade pRB while swapping the HPV1 E7 CR2
domain into the HPV16 E7 background resulted in loss of ability to
Fig. 2. Schematic representation of the HPV E7 CR1 mutants described in
Tables 4 and 5. Amino acid residues 1–14 of HPV16, 31 and 18 E7 are shown. The
one letter code for amino acid (aa) residues is used. Black boxes denote
deletions (del).
Fig. 3. Schematic representation of the HPV E7 CR2 mutants described in
Tables 6 and 7. Amino acid residues 15–39 of HPV16 and HPV31 E7 and amino
acid residues 18–42 of HPV18 E7 are shown. The position of the LXCXE motif is
indicated. The one letter code for amino acid (aa) residues is used; X denotes any
amino acid. Black boxes denote deletions.
Fig. 4. Schematic representation of the HPV E7 C-terminal mutants described in
Tables 8 and 9. Amino acid residues 46–98 of HPV16 and HPV31 E7 and amino acid
residues 53–105 of HPV18 E7 are shown. The positions of the CXXC motifs are
indicated. The one letter code for amino acid (aa) residues is used; X denotes any
amino acid. Black boxes denote deletions.
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sequence to Q27LN29 in HPV16 E7 CR2 (compared to E29VPP32
in HPV1 E7—see Fig. 1) (Giarre et al., 2001).Genetically engineered mouse models
Papillomaviruses are highly species speciﬁc and there are no
infectious heterologous animal models for HPV life cycle and pathogen-
esis studies. Genetically engineered mouse models (GEMMs) with
expression of alpha and beta HPV subgenomic fragments targeted
to basal epithelia recapitulate key phenotypes of the diseases that
these viruses can cause upon infection of the human host (Arbeit
et al., 1996; Brake and Lambert, 2005; Schaper et al., 2005; Viarisio
et al., 2011). GEMMs expressing HPV E7 in basal epithelial cells
have not only validated results from cell-based experiments but in
many cases have also provided novel insights (Balsitis et al., 2006,
2005, 2003; Schaeffer et al., 2004; Shin et al., 2009, 2012b). Of
particular interest are studies that document that E7 is the major
driver of GEMMs for HPV-associated cervical (Jabbar et al., 2009)
and anal (Thomas et al., 2011) cancers. The results from such
studies are summarized in Table 13.
Table 10





CR1 H2R4H5/AAA Retains binding to p130 Zhang et al. (2006)
Fails to destabilize p130
Fails to decrease/delay differentiation
CR1 R4D Retains binding to pRB Sang and Barbosa (1992)
Retains ability to be phosphorylated by CKII
CR1 R4V6K9/DPH Retains ability to transactivate the AdE2 promoter in BRKs and HFKs Armstrong and Roman (1997)
CR1/CR2 R4V6K9G22H24/ DPHDY Super transactivates (greater than HPV16 E7) the AdE2 and
B-myb promoters in HFKs
Armstrong and Roman (1997)




Gains transactivation ability comparable to HPV16 E7 on the
AdE2 promoter in BRKs and HFKs
Armstrong and Roman (1997)
CR1 T7A Retains ability to be phosphorylated by CKII Armstrong and Roman (1995)
Fails to be phosphorylated in vitro by PKC
CR1/CR2 T7G22H24/DDY Super transactivates the AdE2 and B-myb promoters in HFKs Armstrong and Roman (1997)
CR1/CR2 T7G22H24/ADY Gains transactivation ability comparable to HPV16 E7 on the
AdE2 and B-myb promoters in HFKs
Armstrong and Roman (1997)
CR1 K9D10/AA Retains binding to p130 Zhang et al. (2006)
Retains ability to destabilize p130
Retains ability to decrease/delay differentiation
CR2 G22D Increases binding to pRB Sang and Barbosa (1992)
Retains ability to be phosphorylated by CKII
Gains ability to transform permanent rodent cells
Gains ability to destabilize pRB Zhang et al. (2006)
Increases binding to p107
Increases binding to p130
CR2 G22D in context of chimeric
E7 with HPV6 E7 N-terminus
and HPV16 E7 C-terminus
Increases binding to pRB Increases transformation of BRK cells
in cooperation with RAS
Heck et al. (1992)
CR2 G22H24/DY Gains transactivation ability comparable to HPV16 E7 on the
AdE2 promoter in BRKs and HFKs
Armstrong and Roman (1997)
G22H24V37E39/DYDI Gains transactivation ability comparable to HPV16 E7 on the
AdE2 promoter in BRKs and HFKs
Armstrong and Roman (1997)
CR2 C25A Fails to bind p130 Zhang et al. (2006)
Fails to destabilize p130
Fails to decrease/delay differentiation
CR2 V30N Retains binding to pRB Sang and Barbosa (1992)
Increases ability to be phosphorylated by CKII
CR2 D31A Retains binding to p130 Zhang et al. (2006)
Retains ability to destabilize p130
Retains ability to decrease/delay differentiation
CR2 S32S33/AA Fails to be phosphorylated by CKII Armstrong and Roman (1995)
Retains ability to be phosphorylated in vitro by PKC
CR2 V37D Retains binding to pRB Sang and Barbosa (1992)
Increases ability to be phosphorylated by CKII
CR2 V37E39/DI Retains ability to transactivate the AdE2 promoter in BRKs
Loses ability to transactivate the same promoter in HFKs
Armstrong and Roman (1997)
C-term K49T Somewhat increases ability to induce unscheduled suprabasal
DNA synthesis
Genovese et al. (2011)
C-term K49R Somewhat increases ability to induce unscheduled suprabasal
DNA synthesis
Genovese et al. (2011)
C-term L67R Retains binding to p130 Zhang et al. (2006)
Fails to destabilize p130
Fails to decrease/delay differentiation
HPV11
CR2 G22D Increases binding to p130 Genovese et al. (2011)
Reduces ability to destabilize p130
Somewhat increases ability to induce unscheduled
suprabasal DNA synthesis
CR2 G22K39K42/DEA Gains increased ability to induce unscheduled suprabasal DNA
synthesis comparable to HPV16 E7
Genovese et al. (2011)
CR2 G22K39K42/DRR Gains increased ability to induce unscheduled suprabasal DNA
synthesis comparable to HPV16 E7
Genovese et al. (2011)
CR2 del 22–25 (GLHC) Fails to destabilize p130 Genovese et al. (2008)
Fails to induce suprabasal DNA synthesis
CR2 S32S33/NQ Fails to be phosphorylated by CKII Genovese et al. (2008)
Reduces ability to destabilize p130
Fails to induce suprabasal DNA synthesis
CR2/C-term K39K42/EA Somewhat increases ability to induce unscheduled suprabasal
DNA synthesis
Genovese et al. (2011)
CR2/C-term K39K42/RR Somewhat increases ability to induce unscheduled suprabasal
DNA synthesis
Genovese et al. (2011)
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Increases binding to and destabilization of p130
C-term Q78T Retains inability to repress MHC I expression Heller et al. (2011)
C-term Q78Q80/TE Retains inability to repress MHC I expression Heller et al. (2011)
C-term Q78Q80N88/TEG Partially gains ability to repress MHC I expression comparable
to HPV16 E7
Heller et al. (2011)
C-term Q80E Retains inability to repress MHC I expression Heller et al. (2011)
C-term Q80N88/EG Partially gains ability to repress MHC I expression Heller et al. (2011)
C-term N88G Partially gains ability to repress MHC I expression Heller et al. (2011)
BRK, baby rat kidney cells; and HFK, primary human foreskin keratinocytes.
Fig. 5. Schematic representation of the low-risk alpha HPV E7 mutants described in Table 10. A schematic structure of E7 is shown on top with CR1, CR2 and conserved
C-terminal domains indicated in black and the non-conserved regions shown in gray. The positions of the LXCXE motif in CR2 and CXXC motifs in the C-terminus are
indicated. The one letter code for amino acid (aa) residues is used; X denotes any amino acid. Black boxes denote deletions.
Table 11
Experiments with HPV16 E7 derived peptides.
HPV16 E7 Peptide E7 domain Activity References
aa 1–98 CR1/CR2/C-
term
Induces cellular DNA synthesis Rawls et al. (1990)




CR1 Low efﬁciency binding to Siva-1 Severino et al. (2007)
aa 1–17 CR1 Fails to bind p27KIP1 Zerfass-Thome et al. (1996)
aa 1–36 CR1/CR2 Fails to bind DYRK1A Liang et al. (2008)
aa 1–38 CR1/CR2 Fails to bind BRCA1 Zhang et al. (2005)
aa 1–40 CR1/CR2 Fails to induce cellular DNA synthesis Rawls et al. (1990)
Fails to activate the Ad E2 promoter
Fails to bind Zn2+
del 1–38 CR1/CR2 Binds p21CIP1 Funk et al. (1997)
aa 2–32 CR1/CR2 Binds pRB, p107, p130 and cyclin A Dyson et al. (1992)
aa 2–41 Fails to bind MPP2 (FOXM1) Luscher-Firzlaff et al. (1999)
Fails to stimulate MPP2 (FOXM1)-dependent transcription Luscher-Firzlaff et al. (1999)
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HPV16 E7 Peptide E7 domain Activity References
del 9–48 del in CR1/CR2 Retains binding to cdk2 (via cyclin A) He et al. (2003)
del 9–38 del in CR1/CR2 Loses ability to activate cdk2 He et al. (2003)
Overlapping 12-mers
from aa 10–30
CR1/CR2 Fail to bind to Siva-1 Severino et al. (2007)
aa 16–41 CR2 Localizes to nucleus, like full length E7 Fujikawa et al. (1994)
aa 18–38 CR2 Fails to bind p27KIP1 Zerfass-Thome et al. (1996)
aa 21–29 CR2 Minimal E7 peptide that inhibits E7/pRB binding Jones et al. (1990)
aa 20–29 D21N CR2 Fails to inhibit E7/pRB binding Jones et al. (1990)
aa 20–29 Y23F CR2 Fails to inhibit E7/pRB binding Jones et al. (1990)
aa 20–29C24S CR2 Fails to inhibit E7/pRB binding Jones et al. (1990)
aa 20–29 Y25F CR2 Fails to inhibit E7/pRB binding Jones et al. (1990)
aa 20–29 E26Q CR2 Fails to inhibit E7/pRB binding Jones et al. (1990)
aa 20–29 Q27N CR2 Retains ability to inhibit E7/pRB binding Jones et al. (1990)
Overlapping 12-mers
from aa 22–42
CR2 Fails to bind to Siva-1 Severino et al. (2007)
aa 25–36 CR2 Binds IRF-9 Antonsson et al. (2006)
aa 16–98 CR2/C-term Severely defective for cellular DNA synthesis Rawls et al. (1990)
Severely defective for Ad E2 activation
Binds Zn2+
aa31–98 CR2/C-term Necessary for disruption of pRB/E2F-1 complex Huang et al. (1993), Patrick et al. (1994),
Wu et al. (1993)
Overlapping 12-mers
from aa 37–69
C-term Signiﬁcant binding to Siva-1 Severino et al. (2007)
aa 38–98 C-term Binds BRCA1 Zhang et al. (2005)
C-term Binds DYRK1A Liang et al. (2008)
aa 39–98 C-term Binds p27KIP1 Zerfass-Thome et al. (1996)
aa 39–98 C-term Fails to induce cellular DNA synthesis Rawls et al. (1990)
Fails to transactivate the Ad E2 promoter
Binds Zn2+
delta 40–98 del C-term Fails to bind p21CIP1 Funk et al. (1997)
aa 42–98 C-term Binds MPP2 (FOXM1) Luscher-Firzlaff et al. (1999)
C-term Retains the ability to stimulate MPP2 (FOXM1)-dependent
transcription
Luscher-Firzlaff et al. (1999)
aa 62–84 C-term Required for binding to DNMT1 Burgers et al. (2007)
aa 67–98 C-term Fails to induce cellular DNA synthesis Rawls et al. (1990)
Fails to transactivate the Ad E2 promoter
Binds Zn2+
Overlapping 12-mers from aa 70–84 C-term Fails to bind Siva-1 Severino et al. (2007)
Overlapping 12-mers from aa 79–99 C-term Signiﬁcant to maximal binding to Siva-1 Severino et al. (2007)
aa, amino acid residue.
Table 12
Biological and biochemical activities of E7 proteins encoded by cutaneous (beta, gamma, mu) HPVs.
Genus HPV type Phenotype References
Beta
Beta 1 HPV5 E7 Binds pRB with low efﬁciency Yamashita et al. (1993)
Fails to transform established rodent cells
Fails to immortalize primary rodent cells
Weakly transforms primary rodent cells in cooperation with RAS.
In organotypic raft cultures: Signiﬁcantly delays/disrupts HFK
differentiation in the presence of E6
Boxman et al. (2001)
In organotypic raft cultures: Causes hyperkeratosis and papilla-like
structures
Westphal et al. (2009)
Moderately increases suprabasal proliferation
Results in co-expression of Cyclin E and p16INK4A in suprabasal cells.
Upregulates lipocalin-2 in primary adult keratinocyte monolayers and
in differentiated layers of organotypic raft cultures.
Akgul et al. (2011)
Reduces pRB levels Buitrago-Perez et al. (2012)
HPV5 E7 del 26–29 (DLFC) Fails to reduce pRB levels. Buitrago-Perez et al. (2012)
Beta 1 HPV8 E7 Fails to transform established rodent cells Schmitt et al. (1994),
Yamashita et al. (1993)
Binds pRB with low efﬁciency Yamashita et al. (1993)
Fails to immortalize primary rodent cells
Very weakly transforms primary rodent cells in cooperation with RAS.
Weakly immortalizes primary human foreskin keratinocytes Schmitt et al. (1994)
Modestly transactivates the AdE2 promoter
In organotypic raft cultures: Causes hyperkeratinization and
suprabasal PCNA expression
Akgul et al. (2005)
Causes invasion of epidermal cells into artiﬁcial dermis.
Upregulates MT-1-MMP expression and activates MMP-1, 2, 8 Akgul et al. (2005),
Smola-Hess et al. (2005)
Binds SMADs Habig et al. (2006)
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Genus HPV type Phenotype References
Abrogates TGF-β-mediated transactivation
Reduces pRB levels Akgul et al. (2007)
Does not alter p53 or p21CIP1 levels
Causes abnormal keratin expression
Causes polyploidy
In organotypic raft cultures: Moderately increases suprabasal
proliferation
Westphal et al. (2009)
Results in co-expression of Cyclin E and p16INK4A in suprabasal cells.
In organotypic raft and monolayer cultures: Upregulates lipocalin-2. Akgul et al. (2011)
Binds C/EBPβ (GST/Co-IP) Sperling et al. (2012)
Inhibits C/EBPβ-mediated transactivation of CCL20 promoter in
keratinocytes
Inhibits Langerhans cell migration.
HPV8 E7 del 79–83
(FQELL)
Reduces binding to C/EBPβ Sperling et al. (2012)
Fails to inhibit C/EBPβ-mediated transactivation of CCL20 promoter
Beta 1 HPV12 E7 Fails to cooperate with RAS to transform primary rodent cells Massimi et al. (2008)
Beta 1 HPV14 E7 Binds, and in the presence of E6, destabilizes pRB Cornet et al. (2012)
Fails to activate E2F-responsive genes
Fails to immortalize HFKs in the presence of E6
Beta 1 HPV20 E7 In organotypic raft cultures: Causes some delay/disruption of
differentiation in the presence of E6
Boxman et al. (2001)
Binds pRB with low efﬁciency Caldeira et al. (2003)
Fails to destabilize pRB
Fails to abrogate NIH 3T3 growth arrest induced by serum deprivation
In organotypic raft cultures: Moderately increases suprabasal
proliferation;
Westphal et al. (2009)
Fails to cause co-expression of cyclin E and p16INK4A in suprabasal cells
In organotypic raft cultures: Upregulates lipocalin-2 Akgul et al. (2011)
Fails to activate NF-κB Hussain et al. (2011)
Binds Iκκα (Co-IP) Byg et al. (2012)
Attenuates NF-κB-mediated transcription
Beta 1 HPV24 E7 Fails to cooperate with RAS to transform primary rodent cells Massimi et al. (2008)
Binds pRB, and in the presence of E6, partially degrades pRB Cornet et al. (2012)
Causes modest, if any, increase in expression of E2F-responsive
promoters, in the presence of E6
Fails to immortalize HFKs in the presence of E6.
Beta 1 HPV36 E7 Fails to cooperate with RAS to transform primary rodent cells Massimi et al. (2008)
Binds pRB, and in the presence of E6, partially degrades pRB Cornet et al. (2012)
Causes modest, if any, increase in expression of E2F-responsive
promoters, in the presence of E6
Fails to immortalize HFKs in the presence of E6.
Beta 2 HPV22 E7 Binds, and in the presence of E6, destabilizes pRB Cornet et al. (2012)
Fails to activate E2F-responsive genes
Fails to immortalize HFKs in the presence of E6
Beta 2 HPV38 E7 In organotypic raft cultures: Causes some delay/disruption of
differentiation in the presence of E6
Boxman et al. (2001)
Extends life span of primary human ﬁbroblasts and keratinocytes Caldeira et al. (2003)
Binds to pRB with high efﬁciency
Destabilizes pRB in NIH 3T3 and primary human ﬁbroblasts
Abrogates NIH 3T3 growth arrest induced by serum deprivation
Induces anchorage independent growth in NIH 3T3 cells
In organotypic raft cultures: Causes parakeratosis and altered
expression of keratins
Westphal et al. (2009)
Increases suprabasal proliferation
Fails to cause co-expression of cyclin E and p16INK4A in suprabasal cells
Upregulates lipocalin-2 in keratinocyte monolayers and in
differentiated layers of organotypic raft cultures
Akgul et al. (2011)
Binds to eEF1A (GST; Co-IP) Yue et al. (2011)
Downregulates Rho activity
Causes disruption of stress ﬁbers (F-actin) dependent on CKII, MEK,
ERK signaling and eEF1A binding
Binds pRB and enhances phospho-pRB levels in the presence of E6 Cornet et al. (2012)
Activates E2F-responsive genes in the presence of E6
Immortalizes HFKs in the presence of E6
Binds Iκκα (Co-IP) Byg et al. (2012)
Attenuates NF-κB-mediated transcription
Beta 3 HPV49 E7 Fails to cooperate with RAS to transform primary rodent cells Massimi et al. (2008)
Binds pRB and enhances phospho-pRB levels in the presence of E6 Cornet et al. (2012)
Activates E2F-responsive genes in the presence of E6
Immortalizes HFKs in the presence of E6.
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Table 12 (continued )
Genus HPV type Phenotype References
Gamma
Gamma 1 HPV4 E7 In organotypic raft cultures: Causes hyperkeratosis and altered
expression of keratins
Westphal et al. (2009)
Signiﬁcantly increases suprabasal proliferation
Fails to cause co-expression of cyclin E and p16INK4A in suprabasal
cells
Binds pRB through C-terminal sequences (aa 39–100) Wang et al. (2010)
Upregulates lipocalin-2 in primary keratinocyte monolayers but not in
differentiated layers of organotypic raft cultures
Akgul et al. (2011)
Binds Iκκα (Co-IP) Byg et al. (2012)
Attenuates NF-κB-mediated transcription
Gamma 6 HPV108 E7 In organotypic raft cultures: Causes a dysplastic phenotype Nobre et al. (2009)
Mu
Mu 1 HPV1 E7 Binds pRB with high efﬁciency Schmitt et al. (1994)
Transforms permanent rodent cells Fails to immortalize primary HFKs;
Fails to transactivate the Ad E2 promoter
Inability to abrogate C/EBPα-mediated growth arrest Muller et al. (1999)
Inhibits cellular response to IFN-α Barnard et al. (2000)
Fails to destabilize pRB Gonzalez et al. (2001)
Only partially abrogates pRB-mediated senescence in SAOS2 cells
Fails to abrogate p16INK4A-mediated G1 arrest Giarre et al. (2001)
Fails to upregulate MT-1-MMP expression Smola-Hess et al. (2005)
Binds SMADs Habig et al. (2006)
Abrogates TGF-β-mediated transactivation
In organotypic raft cultures: Destabilizes p130 Genovese et al. (2008)
Induces unscheduled DNA synthesis in suprabasal cells
In organotypic raft cultures: Causes hyperkeratosis and dyskeratosis Westphal et al. (2009)
Signiﬁcantly increases suprabasal proliferation
Fails to cause co-expression of cyclin E and p16INK4A in suprabasal cells
Upregulates lipocalin-2 in primary adult keratinocyte monolayers but
not in differentiated layers of organotypic raft cultures.
Akgul et al. (2011)
Binds to p300 with low efﬁciency Fera and Marmorstein (2012)
HPV1 E7 P31P32PI35/SSE Enhances binding to p130 Genovese et al. (2008)
Enhances destabilization of p130 in monolayer and cells induced to
differentiate
Increases induction of suprabasal DNA synthesis
Gains ability to be phosphorylated by CKII
Co-IP, Co-immunoprecipitation; GST, Co-afﬁnity puriﬁcation through association with a glutathione-S-transferase fusion protein; NIH 3T3, immortalized murine ﬁbroblasts;
SAOS2, pRB/p53 defective human osteosarcoma cell line (ATCC Number: HTB-85).
Table 13
Biological activities of HPV E7 in genetically engineered mouse models (GEMMs).




HPV16 E7 Induces cell proliferation, decreases differentiation and apoptosis in the differentiated lens Pan and Griep (1994)




Fails to perturb development in the lens Pan and Griep (1994)
Retinal photoreceptor cell
speciﬁc IRBP promoter
HPV16 E7 Induces p53-dependent apoptosis-mediated retinal degeneration Howes et al. (1994)
Basal epithelial cells
Skin cancer model: Keratin K14 promoter in FVB mice
HPV16 E7 Induces high incidence of squamous epithelial hyperplasia/delayed differentiation Herber et al. (1996)
Induces low incidence of malignant skin tumors
HPV16 E7 Abrogates inhibition of DNA synthesis in response to ionizing radiation Song et al. (1998)
HPV16 E7 Acts as a promoter of skin carcinogenesis Song et al. (2000)
HPV16 E7 Deregulates Mmp2, 12, 14, 19 and 27 genes in E7 induced skin cancer. Ibarra Sierra et al. (2012)
HPV16 E7 When crossed with Rb conditional knock out mice: Causes pRb-independent dysplasia and
increased proliferation
Balsitis et al. (2003)
HPV16 E7 When crossed with RbΔLXCXE knock in mice: Fails to cause epithelial hyperplasia, stimulate cellular
DNA synthesis, abrogate DNA damage induced cell cycle arrest or upregulate p21Cip1
Balsitis et al. (2005)
Retains ability to delay differentiation resulting in expansion of the spinous layer
HPV16 E7 When crossed with p53-/- mice: Retains ability to upregulate p21Cip1 but at a reduced level Balsitis et al. (2005)
HPV16 E7 When crossed with p19Arf-/- mice: Retains ability to upregulate p21Cip1 and p53 Balsitis et al. (2005)
del 6–10
(PTLHE)
Fails to cause epithelial hyperplasia and benign tumors Gulliver et al. (1997)
Fails to abrogate the DNA damage response to radiation Song et al. (1998)
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Table 13 (continued )
Expression site Transgene Phenotype References
del 21–24
(DLYC)
Fails to cause epithelial hyperplasia and benign tumors Gulliver et al. (1997)
Fails to abrogate the DNA damage response to radiation Song et al. (1998)
Cervical carcinoma model: Keratin K14 promoter plus estrogen (0.05 mg/60 days) for 6 months in FVB mice
HPV16 E7 Causes multifocal microinvasive cervical carcinomas, increases the number of centrosomes in
premalignant lesions, and induces p53
Riley et al. (2003)
In combination with E6 (which also increases the number of centrosomes but only causes low
grade dysplasia), causes large, invasive cancers, and greater numbers of centrosomes/cell
HPV16 E7 Signiﬁcantly deregulates Dmbt1, Gli1 and 17βHsd2 genes in E7 induced cervical carcinoma Ibarra Sierra et al.
(2012)
HPV16 E7 When crossed with RbΔLXCXE knock in mice: Fails to stimulate suprabasal DNA synthesis and
abrogate DNA damage response to radiation
Balsitis et al. (2006)
Intermediate ability to up-regulate Mcm7 gene in suprabasal layers
Retains ability to induce cervical carcinomas but without dysplasias
HPV16 E7 Increases expression of p21Cip1 in the suprabasal compartment Shin et al. (2009)
When crossed with p21Cip1-/- mice: Increases the incidence of cervical disease relative to that
seen in p21Cip1-/- mice, but incidence is comparable to that seen in p21Cip1 proﬁcient mice.
HPV16 E7 When crossed with mice carrying a constitutively active β-catenin transgene: Causes higher
incidence of cervical carcinomas than with either transgene alone
Bulut et al. (2011)
C68V69Q70/
AAA
Reduces ability to induce unscheduled DNA synthesis in suprabasal cells Shin et al. (2009)
Retains ability to degrade pRB family members and upregulate Mcm7 and p16Ink4a
Fails to inactivate p21Cip1 and cause severe cervical disease
Cervical carcinoma model: Keratin K5 or 14 promoter plus estrogen (0.05 mg/60 days) for 7–10 months in FVB mice
Repressible
HPV16 E7
When repressed, results in reversion of the acute phenotype and of dysplasia/cancer, whether in
the presence or absence of E6
Jabbar et al. (2009),
Jabbar et al. (2012)
Cervical carcinoma model: Keratin K14 promoter in mixed genetic background
HPV16 E7 8 months estrogen (0.05 mg/60 days): Causes unscheduled DNA synthesis, high incidence of high
grade dysplasia and low incidence of cancer
Chung et al. (2013)
In the absence of stromal but presence of epithelial ERα: Fails to cause unscheduled DNA
synthesis, high grade dysplasia or cancer
Cervical carcinoma model: Conditional knockout of all three Rb family members plus estrogen (0.05 mg/60 days) for 6 months in FVB mice
No transgene Fails to recapitulate the E7-mediated cancer phenotype but does result in a high incidence of high
grade dysplasia
Shin et al. (2012b)
Partially recapitulates the E7-mediated induction of unscheduled DNA synthesis
Totally recapitulates the E7-mediated abrogation of the DNA damage response
Head and Neck Cancer model: Keratin K14 promoter plus low dose 4-NQO in FVB mice
HPV16 E7 Only partially degrades pRb Strati and Lambert
(2007)Increases DNA synthesis in basal cells and induces unscheduled DNA synthesis in suprabasal cells
Causes high incidence of carcinomas and increases expression of Mcm7 and p16Ink4a, similar to
that seen when E6 is expressed along with E7
HPV16 E7 Induces DNA damage foci Park et al. (2010)
When crossed with FancD-/- mice: Enhances induction of DNA damage foci and increases
incidence of carcinomas
Head and Neck Cancer model: Conditional knockout of pRB plus low dose 4-NQO in FVB mice
No
Transgene
Fails to increase DNA synthesis in basal cells but does recapitulate the E7-mediated induction of
unscheduled DNA synthesis in suprabasal cells
Strati and Lambert
(2007)
Causes only a low incidence of carcinomas but does recapitulate the E7-mediated increase in
expression of Mcm7 and p16Ink4a,
Head and Neck Cancer model: Knockout of pRB and p107 plus low dose 4-NQO in FVB mice
No
Transgene
Recapitulates the E7-mediated head and neck disease phenotype and increased expression of
Mcm7, p16Ink4a and Ezh2
Shin et al. (2012a)
Head and Neck Anal Cancer Model: Keratin K14 promoter plus DMBA in FVB mice
HPV16 E7 Causes high incidence of anal cancer (mostly highly differentiated) with increased expression of
Mcm7, p16Ink4a similar to that seen when E6 is expressed along with E7
Thomas et al. (2011)
Induces unscheduled suprabasal DNA synthesis, upregulates Mcm7, and abrogates radiation
induced growth arrest, similar to that seen when E6 is expressed along with E7
DMBA, 7,12-Dimethylbenz(a)anthracene; 4-NQO, 4-Nitroquinoline N-oxide; and mutations are all in the HPV16 E7 gene.
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